EP1594434B1 - Parenteral formulations of peptides for the treatment of systemic lupus erythematosus - Google Patents
Parenteral formulations of peptides for the treatment of systemic lupus erythematosus Download PDFInfo
- Publication number
- EP1594434B1 EP1594434B1 EP04702215.7A EP04702215A EP1594434B1 EP 1594434 B1 EP1594434 B1 EP 1594434B1 EP 04702215 A EP04702215 A EP 04702215A EP 1594434 B1 EP1594434 B1 EP 1594434B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ala
- gly
- ser
- glu
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 271
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims description 198
- 239000000203 mixture Substances 0.000 title claims description 59
- 102000004196 processed proteins & peptides Human genes 0.000 title description 116
- 238000011282 treatment Methods 0.000 title description 75
- 238000009472 formulation Methods 0.000 title description 25
- 229960004853 betadex Drugs 0.000 claims description 118
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 115
- 239000008194 pharmaceutical composition Substances 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 59
- 229920000858 Cyclodextrin Polymers 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 43
- 230000008569 process Effects 0.000 claims description 39
- 239000001116 FEMA 4028 Substances 0.000 claims description 38
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 37
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 239000008137 solubility enhancer Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 14
- -1 hydroxypropyl Chemical group 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 108010061238 threonyl-glycine Proteins 0.000 claims description 11
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 claims description 9
- 159000000021 acetate salts Chemical group 0.000 claims description 8
- 239000008365 aqueous carrier Substances 0.000 claims description 8
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 claims description 6
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 5
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical group OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 claims description 3
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 claims description 3
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 claims description 3
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 claims description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 claims description 3
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 claims description 3
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims description 3
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 claims description 3
- YWWATNIVMOCSAV-UBHSHLNASA-N Ala-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YWWATNIVMOCSAV-UBHSHLNASA-N 0.000 claims description 2
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 claims description 2
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 claims description 2
- ILKYYKRAULNYMS-JYJNAYRXSA-N Gln-Lys-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ILKYYKRAULNYMS-JYJNAYRXSA-N 0.000 claims description 2
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 claims description 2
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 claims description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 claims description 2
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 claims description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 claims description 2
- QWTGQXGNNMIUCW-BPUTZDHNSA-N Met-Asn-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QWTGQXGNNMIUCW-BPUTZDHNSA-N 0.000 claims description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 claims description 2
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 claims description 2
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 claims description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 claims description 2
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 claims description 2
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 claims description 2
- DXDMNBJJEXYMLA-UBHSHLNASA-N Trp-Asn-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 DXDMNBJJEXYMLA-UBHSHLNASA-N 0.000 claims description 2
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 claims description 2
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 claims description 2
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 claims description 2
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 claims description 2
- COSLEEOIYRPTHD-YDHLFZDLSA-N Val-Asp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 COSLEEOIYRPTHD-YDHLFZDLSA-N 0.000 claims description 2
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 claims description 2
- 108010077245 asparaginyl-proline Proteins 0.000 claims description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 2
- 108010015792 glycyllysine Proteins 0.000 claims description 2
- 108010084389 glycyltryptophan Proteins 0.000 claims description 2
- 108010087823 glycyltyrosine Proteins 0.000 claims description 2
- 108010000761 leucylarginine Proteins 0.000 claims description 2
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 claims description 2
- VMSUVWZFCQSDRU-UHFFFAOYSA-N 3-(3-sulfopropoxy)propane-1-sulfonic acid Chemical group OS(=O)(=O)CCCOCCCS(O)(=O)=O VMSUVWZFCQSDRU-UHFFFAOYSA-N 0.000 claims 1
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 claims 1
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 claims 1
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 claims 1
- ARIORLIIMJACKZ-KKUMJFAQSA-N Glu-Pro-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ARIORLIIMJACKZ-KKUMJFAQSA-N 0.000 claims 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 claims 1
- QPBJXNYYQTUTDD-KKUMJFAQSA-N Tyr-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QPBJXNYYQTUTDD-KKUMJFAQSA-N 0.000 claims 1
- 108010078144 glutaminyl-glycine Proteins 0.000 claims 1
- 108010073101 phenylalanylleucine Proteins 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 description 123
- 230000000694 effects Effects 0.000 description 92
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 84
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 84
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 80
- 239000000243 solution Substances 0.000 description 77
- 241000699666 Mus <mouse, genus> Species 0.000 description 73
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 67
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 65
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 60
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 53
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 49
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 47
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 40
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 37
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 29
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 26
- 229940068196 placebo Drugs 0.000 description 26
- 239000000902 placebo Substances 0.000 description 26
- 230000028327 secretion Effects 0.000 description 26
- 108010002350 Interleukin-2 Proteins 0.000 description 25
- 102000000588 Interleukin-2 Human genes 0.000 description 25
- 238000012360 testing method Methods 0.000 description 23
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 19
- 229940126534 drug product Drugs 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000000825 pharmaceutical preparation Substances 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 19
- 230000009696 proliferative response Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 18
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 206010025135 lupus erythematosus Diseases 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 230000009266 disease activity Effects 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000003172 anti-dna Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 108010062580 Concanavalin A Proteins 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229940068968 polysorbate 80 Drugs 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 239000002254 cytotoxic agent Substances 0.000 description 8
- 231100000599 cytotoxic agent Toxicity 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 108010047620 Phytohemagglutinins Proteins 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000001885 phytohemagglutinin Effects 0.000 description 7
- 201000001474 proteinuria Diseases 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000003430 antimalarial agent Substances 0.000 description 6
- 238000003149 assay kit Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 229940113088 dimethylacetamide Drugs 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960003646 lysine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 229940068977 polysorbate 20 Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 206010035742 Pneumonitis Diseases 0.000 description 5
- 208000003782 Raynaud disease Diseases 0.000 description 5
- 208000012322 Raynaud phenomenon Diseases 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 229960003121 arginine Drugs 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 238000000326 densiometry Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229960000814 tetanus toxoid Drugs 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000004389 Ribonucleoproteins Human genes 0.000 description 4
- 108010081734 Ribonucleoproteins Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000000078 anti-malarial effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000007804 gelatin zymography Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000020402 negative regulation of interleukin-2 secretion Effects 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 235000019766 L-Lysine Nutrition 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100030416 Stromelysin-1 Human genes 0.000 description 3
- 101710108790 Stromelysin-1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003429 anti-cardiolipin effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000012395 formulation development Methods 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 201000002364 leukopenia Diseases 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000012792 lyophilization process Methods 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 206010067982 Butterfly rash Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010058556 Serositis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229920005605 branched copolymer Polymers 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 102000049265 human CDR1 Human genes 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920005684 linear copolymer Polymers 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- UEJBEYOXRNGPEI-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)propan-1-one Chemical compound CNC(C)C(=O)C1=CC=C(Cl)C=C1 UEJBEYOXRNGPEI-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- 241000205762 Crithidia luciliae Species 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- WGAZVKFCPHXZLO-SZMVWBNQSA-N Leu-Trp-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N WGAZVKFCPHXZLO-SZMVWBNQSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical class CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000012263 renal involvement Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- SLE Systemic lupus erythematosus
- lupus is a debilitating autoimmune disease characterized by the presence of an array of autoantibodies, including antibodies to dsDNA, to nuclear antigens and to ribonucleoproteins.
- SLE affects approximately 1 in 2000 individuals (U.S. 1 in 700 women). The disease primarily affects young women, with a female-to male ratio of approximately 9:1.
- Systemic lupus can affect almost any organ or system of the body.
- Systemic lupus may include periods in which few, if any, symptoms are evident (“remission”) and other times when the disease becomes more active (“flare”). Most often when people mention “lupus,” they are referring to the systemic form of the disease.
- Corticosteroids are the mainstay in treating systemic autoimmune disorders. Life threatening, severely disabling manifestations of SLE are treated with high doses of glucocorticoids (1-2 mg/kg/day). Undesirable effects of chronic glucocorticoids include an array of prominent adverse effects such as cushingoid habitus, central obesity, hypertension, infection, capillary fragility, hirsutism, accelerated osteoporosis, cataracts, diabetes mellitus, myopathy and psychosis. In addition to corticosteroid toxicity, patient compliance to a dosage regimen also poses a serious problem.
- Cytotoxic agents are also used for controlling active disease, reducing the rate of disease flares, and reducing steroid requirements.
- Undesirable side effects of the latter include bone marrow depression, increased infections with opportunistic organisms, irreversible ovarian failure, alopecia and increased risk of malignancy.
- SLE is an inflammatory disease for which to date there is no definitive treatment or cure.
- the disease results in acute and chronic complications.
- the only treatments available are palliative, aimed at relieving acute symptoms and preventing chronic complications, often with profound side effects. There is therefore an unmet need in this field, and both physicians and patients would welcome new treatments which could potentially eliminate or reduce the unwanted manifestations of the disease.
- the human mAB 16/6 is an anti-DNA antibody originally of the IgM isotype and switched in culture to IgG1.
- the mAB was derived from a patient and expresses a common idiotype, the 16/6 Id (Shoenfeld et al., 1983; Mendlovic et al., 1988).
- the hybridoma cells secreting this mAB are routinely grown in culture, and the antibody is isolated from culture supernatants using an affinity column of Protein G coupled to SepharoseTM.
- the human 16/6 anti-DNA mAB (IgG1/ ⁇ ) was described in Shoenfeld, Y. et al., J. Clin. Invest. 70: 205-208 (1982 ) and in Waisman, A. et al., Int. Immunol. 7: 689-696 (1995 ).
- mice Following immunization, the mice produced antibodies specific to the 16/6 Id, antibodies that bear the 16/6 Id and antibodies directed against different nuclear antigens (dsDNA, ssDNA, Sm, ribonucleoprotein (RNP), Ro, La and others).
- the serological findings were associated with leukopenia, elevated erythrocyte sedimentation rate, proteinuria, abundance of immune complexes in the kidneys and sclerosis of the glomeruli (Mendlovic et al., 1988), which are typical manifestations of SLE. It was further shown that the experimental disease could be induced by a murine anti-16/6 Id mAb ( Mendlovic, S. et al., Eur. J. Immunol.
- SLE is a systemic autoimmune disease characterized by the formation of auto antibodies against self-antigens, such as DNA, Sm, Ro, La, RNP, cardiolipin and histones.
- self-antigens such as DNA, Sm, Ro, La, RNP, cardiolipin and histones.
- the etiology of SLE is unknown, and understanding the mechanism by which these self-antibodies arise provided insight.
- Monoclonal autoantibodies that were capable of eliciting antibodies that bear the 16/6 Id or react with it were found to be pathogenic and thus capable of inducing experimental SLE ( Fricke, H. et al., Internatl. Immunol. 2: 225 (1990 ); Sthoeger, Z.M. et al., J. Clin. Immunol. 13: 127 (1993 )).
- V H heavy chain V region gene
- the light (L) chain V region gene (V L ) of mAb 2C4C2 is 98% homologous to the V L of another anti-DNA mAb, also isolated from (NZB xNZW)F 1 mice.
- the other two anti-DNA mAb designated 5G12-4 and 5G12-6, share 93% of their V H sequences with that of mAb 2C4C2.
- the nine mAb use a total of five V H and four V L germ-line genes, demonstrating that the autoantibodies induced in mice with experimental SLE do not originate from one B cell clone. Three of the nine V H and V L were identical in sequence to germ-line genes, while at least three others had somatic mutations.
- mice with experimental SLE use genetic elements similar to those used by mAb that were isolated from mouse strains which develop lupus spontaneously.
- T cell lines and clones specific to the 16/6 Id were shown to induce experimental SLE in syngeneic recipients similarly to the 16/6 antibody. Therefore, following the inoculation of the activated cells of the lines, the mice developed both the serology and the renal damage which is typical to SLE ( Fricke, H. et al., Immunology 73: 421 (1991 )).
- a 16/6 Id specific T cell line of C3H.SW origin induced SLE in C57BL/6 mice that were shown to be resistant to the induction of the disease following injections with either the 16/6 Id or the anti-16/6Id mAb (Mendlovic et al., 1990).
- the mAb 5G12 that was isolated from mice with experimental SLE and was shown to bind DNA and bear the 16/6. Id, is capable of inducing experimental SLE in mice ( Waisman, A. et al., Internatl. Immunol. 5:1293 (1993 )).
- Human CDR1 is a synthetic peptide of 19 amino acids based on the complementarity-determining region 1 (CDR1) of the human anti-dsDNA mAb denoted 16/6 Id ( Waisman, A., et al. "Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti-DNA monoclonal antibodies.” Proc. Natl. Acad. Sci. U.S.A. (1997), 94(4): 4620-4625 ).
- CDR1 complementarity-determining region 1
- WO02/067848 A2 discloses a pharmaceutical composition comprising synthetic peptides of at least 12 and at most 30 amino acids residues, including peptides having the sequences as denoted by SEQ ID NO: 6-10,16,17 with a pharmaceutically acceptable carrier for parenteral administration. It also discloses the use thereof for treating Systemic Lupus Erythematosus (SLE).
- SLE Systemic Lupus Erythematosus
- WO9630057 A1 discloses a pharmaceutical composition comprising synthetic peptides of at least 12 and at most 30 amino acids residues, including peptides having the sequences as denoted by SEQ ID NO: 1-5,11-15 with a pharmaceutically acceptable carrier for parenteral administration. It also discloses the use thereof for treating Systemic Lupus Erythematosus (SLE).
- SLE Systemic Lupus Erythematosus
- the subject invention provides a pharmaceutical composition comprising:
- the subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject any of the pharmaceutical compositions of the invention in an amount effective to alleviate the symptoms of SLE in the human subject.
- SLE systemic lupus erythematosus
- the subject invention provides a pharmaceutical composition comprising:
- At least 0.5 mg/ml of the composition is the pharmaceutically acceptable salt of the peptide.
- the peptide has a sequence selected from the group consisting of:
- the peptide comprises consecutive amino acids having the sequence
- the substituted ⁇ -cyclodextrin is a hydroxypropyl, a sulfobutyl ether, or asulfopropyl ether substituted ⁇ -cyclodextrin.
- the substituted ⁇ -cyclodextrin is a substituted sulfobutyl ether ⁇ -cyclodextrin.
- the concentration of peptide in solution is at least 1 mg/ml.
- the concentration of peptide in solution is at least 2.5 mg/ml.
- the concentration of the salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 0.5 mg/ml to 2.5 mg/ml.
- the concentration of the salt of the peptide is from 2.5 mg/ml to 5 mg/ml.
- the concentration of the salt of the peptide is from 5 mg/ml to 7 mg/ml.
- the concentration of the salt of the peptide is from 7 mg/ml to 8.5 mg/ml.
- the concentration of the salt of the peptide is from 8.5 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 9 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 10 mg/ml to 15 mg/ml.
- the concentration of the salt of the peptide is from 15 mg/ml to 20 mg/ml.
- the concentration of the salt of the peptide is 1.0 mg/ml.
- the concentration of the salt of the peptide is 2.5 mg/ml.
- the concentration of the salt of the peptide is 5 mg/ml.
- the concentration of the salt of the peptide is 10 mg/ml.
- the concentration of the salt of the peptide is 15 mg/ml.
- the concentration of the salt is from 0.1 mg/ml to 0.5 mg/ml.
- the concentration of the salt is from 0.1 mg/ml to 0.2 mg/ml.
- the concentration of the salt is from 0.2 mg/ml to 0.3 mg/ml.
- the concentration of the salt is from 0.3 mg/ml to 0.4 mg/ml.
- the concentration of the salt is from 0.4 mg/ml to 0.5 mg/ml.
- the composition has a pH between 6.5 and 8.5.
- the composition has a pH between 7.5 and 8.5.
- the composition has a pH between 4 and 5.
- the composition has a pH between 5 and 6.
- the composition has a pH between 6 and 7.
- the composition has a pH between 7 and 8.
- the composition has a pH between 8 and 9.
- the pharmaceutically acceptable salt is an acetate salt.
- the pharmaceutically acceptable salt is an acetate salt
- the substituted ⁇ -cyclodextrin is hepta-(sulfobutyl ether)- ⁇ -cyclodextrin.
- the composition further comprises a pharmaceutically acceptable buffer in an amount and of a type suitable to make the pH of the pharmaceutical composition in the range of 4-9.
- the buffer may be acetate buffer, citrate buffer, or sodium carbonate.
- the subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject any of the above pharmaceutical compositions in an amount effective to alleviate the symptoms of the SLE in the human subject.
- SLE systemic lupus erythematosus
- the subject invention also provides any of the above pharmaceutical compositions for use in treating SLE in a human subject.
- the subject invention also provides a process for manufacturing any of the above pharmaceutical compositions comprising the steps of:
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of at least 0.1 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of at least 0.5 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of 2.5mg/ml, 2.0mg/ml, 1.0mg/ml, 0.5 mg/ml or 0.1 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is 5 mg/ml, 10 mg/ml or 15 mg/ml.
- the resulting final concentration of the substituted ⁇ -cyclodextrin in the pharmaceutical composition is from 70 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 80 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 90 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 100 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a. final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 110 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 120 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 130 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 140 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 150 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 160 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition is 120 mg/ml.
- step b) further comprises mixing the solution for 1 hour.
- step c) the pH is adjusted using HCl or NaOH 1.0N.
- the process further comprises filtering the solution of step d) through a cellulose acetate filter.
- the subject invention also provides a composition prepared by any of the above processes.
- the subject invention also provides a lyophilized pharmaceutical composition comprising from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of
- the lyophilized pharmaceutical composition at least 0.5 mg/ml of the composition is the pharmaceutically acceptable salt of the peptide.
- the subject invention also provides a process of lyophilizing any of the above pharmaceutical compositions comprising the steps of:
- step a) is performed within 2 hours.
- step b) is performed within 3 hours.
- step c) is performed over 13 hours.
- step c) is performed at a pressure of 110 ⁇ bar.
- step d) is performed over 13 hours.
- step d) is performed at a pressure of 110 ⁇ bar.
- step e) the pressure is reduced to 10 ⁇ bar.
- step e) is performed over 5 hours.
- the subject invention also provides a lyophilized pharmaceutical composition prepared by any of the above processes.
- the subject invention also provides a process of lyophilizing any of the above pharmaceutical compositions comprising the steps of:
- step a) is performed within 6 hours.
- step b) is performed within 3 hours.
- step c) is performed over 19 hours.
- step c) is performed at a pressure of 150 ⁇ bar.
- step d) is performed over 13 hours.
- step d) is performed at a pressure of 150 ⁇ bar.
- step e) is performed over 8 hours.
- step e) is performed at a pressure of 150 ⁇ bar.
- the subject invention also provides a lyophilized pharmaceutical composition prepared by any of the above processes.
- the subject invention also provides the above lyophilized pharmaceutical composition wherein the water content of the composition is less than 5%.
- the water content of the composition is less than 4.0%.
- the water content of the composition is less then 3.5%.
- the subject invention also provides a packaged pharmaceutical composition comprised of:
- the peptide has the formula
- the synthetic peptides of this invention are based on the CDR of monoclonal pathogenic autoantibodies isolated from mice with experimental SLE.
- monoclonal antibodies are obtained from supernatants of hybridomas produced by fusion, for example, of spleen cells of C3H.SW mice immunized with an anti-16/6 Id mAb, with X63.653 plasmacytoma cells (Waisman and Mozes, 1993).
- Examples of such peptides are those of formulas Ia to Va herein, based on, respectively, the CDR1, CDR2 and CDR3 regions of the heavy chain of mAb 5G12 and the CDR1 and CDR3 regions of the heavy chain of mAb 2C4C2 (Waisman and Mozes, 1993), and analogs thereof.
- Peptides of the present invention are intended to include analogs of peptides Ia-Va including substitution, deletion and addition analogs as described herein.
- Substitution analogs have amino acid substitutions at different positions, these substitutions being made based on the volume, hydrophobic-hydrophilic pattern and charge of the amino acids.
- Amino acids may be divided along the lines of volume, hydrophobic-hydrophilic pattern and charge.
- volume those of ordinary skill in the art understand that the amino acids with the largest volume are Trp, Tyr, Phe, Arg, Lys, Ile, Leu, Met and His, while those with the smallest volumes are Gly, Ala, Ser, Asp, Thr and Pro, with others being in between.
- hydrophobic-hydrophilic pattern it is well known that the amino acids Gly, Ala, Phe, Val, Leu, Ile, Pro, Met and Trp are hydrophobic, whereas all of the remaining amino acids are hydrophilic.
- hydrophilic amino acids Ser, Thr, Gln, and Tyr have no charge, while Arg, Lys, His and Asn have a positive charge and Asp and Glu have negative charges.
- a hydrophobic residue may be substituted with a hydrophilic residue, or vice-versa, as long as the total effect does not substantially change the volume, hydrophobic-hydrophilic pattern and charge of the corresponding unsubstituted parent peptide.
- the peptide of the present invention is intended to include a "chemical derivative" thereof which retains at least a portion of the function of the peptide which permits its utility in preventing or inhibiting T cell proliferative responses and autoimmune disease.
- a "chemical derivative" of a peptide of the present invention contains additional chemical moieties not normally a part of the peptide. Covalent modifications of the peptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Many such chemical derivatives and methods for making them are well known in the art.
- salts of the peptides of the invention are also included in the scope of the invention.
- the term “salts” refers to both salts of carboxyl groups and to acid addition salts of amino groups of the peptide molecule.
- Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases such as those formed for example, with amines, such astriethanolamine, arginine, or lysine, piperidine, procaine, and the like.
- Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid.
- mineral acids such as, for example, hydrochloric acid or sulfuric acid
- organic acids such as, for example, acetic acid or oxalic acid.
- Such chemical derivatives and salts are preferably used to modify the pharmaceutical properties of the peptide insofar as stability, solubility, etc., are concerned.
- the synthetic peptides and analogs thereof according to the invention may be selected from the group consisting of peptides having the sequences I to V herein, wherein:
- the peptide of sequence V has the formula (Va) (SEQ ID NO:5): YYCARSGRYG N Y W GQ T L (Va).
- Peptides Ia to IIIa are based on the CDR1, CDR2 and CDR3 regions, respectively, of the V H chain of mAb5G12, and peptides IVa and Va are based on the CDR1 and CDR3 regions, respectively, of the V H chain of mAb 2C4C2 (Waisman and Mozes, 1993).
- a peptide in accordance with the present invention is produced, its ability to inhibit the proliferative response of T lymphocytes of mice that are high responders to SLE inducing autoantibodies may be readily determined by those of ordinary skill in the art without undue experimentation using tests such as those described herein.
- One test which may be readily conducted is for the ability of substituted peptides to inhibit in vitro the proliferative responses of certain T cell lines and clones specific to SLE-inducing autoantibodies.
- the T cell lines and clones may, for example, be the T cell lines and clones specific to the 16/6 Id mAb (Fricke et al., 1991) established from immunized lymph node cells of mice by previously described methodology (Axelrod, O. and Mozes, E.
- Another test which can be conducted in order to select peptides having the desired activity is to test for the ability of the substituted peptides to inhibit the ability of the T cell lines and clones to provide help to peptide-specific B cells in the presence of the parent peptide.
- the substituted peptides may also be tested for their ability to bind directly, following biotinylation, to MMC Class II products on antigen-presenting cells of the relevant strains.
- N-terminal biotinylation of the relevant peptides is performed at 0oC with an excess of biotin-N-hydroxysuccinimide in aqueous solution ( Mozes, E. et al., EMBO J. 8: 4049 (1989 )).
- Mouse splenic adherent cells or human peripheral blood lymphocyte (PBL)-adherent cells (1x10 6 /sample) are incubated with biotinylated peptides in PBS containing 0.1% bovine serum albumin (PBS/BSA) at 37oC for 20 hr, followed by incubation with phycoerythrin-streptavidin for 30 min at 4oC. After each incubation, the cells are washed twice with the above solution. Thereafter, the cells are analyzed by flow cytometry using FACScan. In each analysis, a minimum of 5000 cells are examined (for above procedures, see, for example, Mozes et al., 1989; Zisman et al., 1991).
- a further test which can be conducted is to test for the ability of the peptides to inhibit cytokine secretion by the T cell line or by T lymphocytes of mice that are high responders to SLE-inducing autoantibodies.
- the cytokines are detected as follows: IL-1 activity is assessed either by ELISA using a pair of capture and detecting antibodies (as described below for IL-4, IL-6, IL-10) or using the LBRM-33(1A5) assay ( Conlon, P.J. J. Immune.
- IL-4, IL-6, IL-10, INF ⁇ and TNF ⁇ in the supernatants are determined by ELISA using antibodies to the various cytokines (Phamingen, San Diego, Ca., USA) according to the manufacturer's instructions.
- mice which test positive in one or more of these in vitro tests will provide a reasonable expectation of in vivo activity.
- in vivo tests can also be conducted without undue experimentation.
- adult mice may be injected with the candidate peptide at either day -3 or day 0.
- the mice are then immunized with the disease-inducing autoantibody or with the peptide.
- lymph node cells of the mice are tested for their ability to proliferate to the immunogen in order to find out the inhibitory capacity of the candidate peptide.
- Another such in vivo animal test consists in measuring the therapeutic activity directly in the murine model in vivo for the production of SLE as described above.
- the peptides can be injected into the mice in which experimental SLE is induced by different routes at different dosages and at different time schedules.
- biotinylated derivatives of the peptides In order to determine the pharmacokinetic parameters of the peptides, including volume of distribution, uptake into antigen-presenting cells and clearance, one can use biotinylated derivatives of the peptides.
- the concentration of the soluble fraction of the peptides in the various body fluids can be determined by ELISA, using avidin-coated plates and specific anti-peptide antibodies.
- Cell bound peptides can be analyzed by FACS, using fluorochromo-conjugated avidin or streptavidin. Furthermore, the treated mice can be tested periodically in order to determine the effect of the peptides on the autoantibody responses and on disease manifestations elicited in the mice by the SLE-inducing autoantibody.
- Another in vivo procedure consists in tolerizing newborn mice with the candidate peptide followed by immunization of the mice with the pathogenic autoantibody, such as 16/6 Id+, or with the same peptide, and following the disease manifestations, such as serological findings associated with leukopenia, elevated erythrocyte sedimentation rate, proteinuria, abundance of immune complexes in the kidneys and sclerosis of the glomeruli.
- a relatively simple in vitro test can also be conducted in order to assay for the expected therapeutic efficacy of any given substituted peptide on any given SLE patient.
- the peptides may be assayed, following biotinylation, for their ability to bind directly to HLA Class II products on antigen-presenting cells in the peripheral blood lymphocytes of the SLE patients. Healthy control donors and control peptides may be used in such assays-to verify their specificity.
- the therapeutic agent of the invention is a peptide selected from the group of peptides of formulas I to V herein, including peptides Ia to Va and substitution and/or deletion analogs thereof.
- the therapeutic agent in accordance with the present invention is the form of a multi-epitope single peptide.
- dual petides consisting of two different peptides selected from the group of peptides of formulas I-V herein, are covalently linked to one another, such as by a short stretch of alanine residues or by a putative site for proteolysis by cathepsin. See, for example, U.S. Patent 5,126,249 and European Patent 495,049 with respect to such sites. This will induce sitespecific proteolysis of the preferred form into the two desired analogs.
- a number of the same or different peptides of the present invention may be formed into a peptide polymer, such as, for example, polymerization of the peptides with a suitable polymerization agent, such as 0.1% glutaraldehyde ( Audibert et al. (1981), Nature 289:593 ).
- the polymer will preferably contain from 5 to 20 peptide residues.
- Such peptide polymers may also be formed by crosslinking the peptides or attaching multiple peptides to macromolecular carriers.
- Suitable macromolecular carriers are, for example, proteins, such as tetanus toxoid, and linear or branched copolymers of amino acids, such as a linear copolymer of L-alanine, L-glutamic acid and L-lysine and a branched copolymer of L tyrosine, L-glutamic acid, L-alanine and L-lysine (T,G)-A-L-, or multichain poly-DLalanine ( M. Sela et al. 1955, J. Am. Chem. Soc. 77:6175 ).
- proteins such as tetanus toxoid
- linear or branched copolymers of amino acids such as a linear copolymer of L-alanine, L-glutamic acid and L-lysine and a branched copolymer of L tyrosine, L-glutamic acid, L-alanine and L-lysine (T,G)
- the conjugates are obtained, for example, by first coupling the peptide with a water-soluble carbodiimide, such as 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride, and then performing the conjugation with the macromolecular carrier as described by Muller, G.M. et al. (1982) Proc. Natl.Acad. Sci. USA 79:569 .
- the contents of the coupled peptide in each conjugate are determined by amino acid analysis, in comparison to the composition of the carrier alone.
- one or more active peptides may be attached to a suitable macromolecular carrier or may be polymerized in the presence of glutaraldehyde.
- the peptides, polymers thereof or their conjugates with suitable macromolecular carriers will be given to patients in a form that insures their bioavailability, making them suitable for treatment. If more than one peptide is found to have significant inhibitory activity, these peptides will be given to patients in a formulation containing a mixture of the peptides.
- the invention further includes pharmaceutical compositions comprising at least one synthetic peptide according to the invention, a conjugate thereof with a suitable macromolecular carrier or a polymer thereof optionally with a pharmaceutically acceptable carrier.
- Any suitable route of administration is encompassed by the invention, including oral, intravenous, subcutaneous, intraarticular, intramuscular, inhalation, intranasal, intrathecal, intraperitoneal, intradermal, transdermal or other known routes, including the enteral route.
- the dose ranges for the administration of the compositions of the present invention should be large enough to produce the desired effect, whereby, for example, an immune response to the SLE-inducing autoantibody, as measured by T cell proliferation in vitro, is substantially prevented or inhibited, and further, where the disease is significantly treated.
- the doses should not be so large as to cause adverse side effects, such as unwanted cross reactions, generalized immunosuppression, anaphylactic reactions and the like.
- Effective doses of the peptides of this invention for use in treating SLE are in the range of 1 ⁇ g/kg to 1 mg/kg body weight.
- the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the synthetic peptides of the invention are aimed at inhibiting or suppressing specific antigen responses of SLE patients, without affecting all other immune responses.
- This approach is of the utmost importance since most diagnosed patients are young women that have to be treated for many years and the currently accepted treatment for SLE involves administration of immunosuppressive agents, such as corticosteroids and/or cytotoxic drugs, that are both non-specific and have multiple adverse side effects.
- the preparations of the present invention may be given parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered by injection, inhalation, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- Synthetic peptides can be produced as described in PCT International Publication No. WO 02/067848 , or in PCT International Publication No. WO 96/30057 .
- peptides of the subject application are described in PCT International Publication No. WO 02/067848, published September 6, 2002 , and can be prepared by methods well known in the art, (see, for example, Peptides: Synthesis, Structure and Applications, ed. by B. Gutte, Academic Press, 1995 ; Peptide Synthesis Protocols, ed. By M. Pennington and B. Dunn, Humana Press, 1994 ; Schnolzer, M. et al., "In situ neutralization in Boc-chemistry solid phase synthesis. Rapid, High yield assembly of difficult sequences.” Int. J. Pept. Protein Res. (1992) 40: 180-193 ).
- Compound 1 is a synthetic polypeptide composed of 19 amino acids. It is provided as an acetate salt. The aqueous solubility of the peptide has been determined to be less than 0.5 mg/ml. Figure 1 shows compound 1 as an acetate salt.
- Compound 1 was dissolved in the chosen solubility enhancer solution either separately or in combination with other excipients and the solutions were stirred for at least an hour. The pH was adjusted if needed. The solutions were visually examined to estimate the solubility and sent for analytical assay determination. For a few chosen formulations, biological activity was also tested.
- Table 1 presents the type of solubility enhancers used for the formulation development.
- Tables 2 and 3 summarize the experiments that were performed with the various solubility enhancers.
- Table 2 summarizes the initial screening performed with peptide concentrations in the range of 5 to 10 mg/ml. The experimental work that was performed with higher peptide concentration was then repeated with the lower doses (see table 3).
- Non aqueous solvents such as Ethanol, Glycerin, Propylene glycol, Chremophore and their combinations were tested but did not increase the solubility of Compound 1.
- a solution of 30% DMA (dimethyl-acetamide) yielded solubility in the desired ranges (5 to 9 mg/ml), but was not suitable for a pharmaceutical formulation due to its toxicity profile. Improved solubility was also observed using 30% (w/w) PEG 400 (5 to 9 mg/ml). This latter formulation was chosen for the toxicology studies, but it has proved to be both inactive in the biological assay, and may have been the cause of some adverse effects in a mouse toxicity study. Thus, it was decided not to further pursue this formulation. In view of the preliminary experiments non-aqueous solvents were not used in the subject formulations.
- Co-solvents see table 1
- Polysorbate 20 and Polysorbate 80 were tested alone and in combination with other excipients. While lower concentrations of Polysorbates (up to 6%) did not improve the solubility of the peptide, higher concentrations (up to 10% - see table 2) improved the solubility of the peptide up to 2 mg/ml. However, such high concentrations of Polysorbates were deemed unsuitable for pharmaceutical formulations.
- cyclodextrins Two types of cyclodextrins, both approved for use in marketed parenteral products, were also tested: Hydroxypropyl- ⁇ -cyclodextrin and Sulfobutylether- ⁇ -cyclodextrin (Captisol). Both markedly increased the solubility of the peptide (concentrations in the levels of 10 mg/ml for Hydroxypropyl- ⁇ -cyclodextrin and 2.5 for Captisol). The biological activity of the two cyclodextrin formulations was tested and was found to be equal to the activity of the peptide alone.
- CAPTISOL® is a commercially available polyanionic ⁇ -cyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl ether spacer group, or sulfobutylether (SBE).
- SBE sulfobutylether
- CAPTISOL® is the trade name for CyDex Inc.'s hepta-substituted sulfobutylether ⁇ -cyclodextrin (SBE7- ⁇ -CD) preparation (www.captisol.com).
- SBE7- ⁇ -CD sulfobutylether
- CAPTISOL® is hydrophilic, the solubility of the complexed drug molecule is thereby enhanced.
- the use of cyclodextrins to enhance the solubility of drug molecules is disclosed in U.S. Patent Nos. 5,134,127 and 5,376,645 .
- CAPTISOL® is safe when administered parenterally and does not exhibit the nephrotoxicity associated with beta-cyclodextrin. Relative to beta-cyclodextrin, CAPTISOL® provides comparable or higher complexation characteristics and superior water solubility in excess of 90 grams/100ml - a 50-fold improvement.
- solubility enhancers were found to match the desired solubility range: DMA, PEG-400, dimethyl-acetamide, polyethylene glycol, polyoxylated castor oil, N-methyl-2-pyrrolidinone, 1-ethenyl-2-pyrrolidinone, Polysorbate 20, Polysorbate 80, Hydroxypropyl- ⁇ -cyclodextrin and Sulfobutylether- ⁇ -cycldextrin (Captisol®).
- DMA solubility enhancers both cyclodextrins have proven to be superior with respect to solubility, biological activity and stability.
- Captisol® as the solubility enhancer for use in Example 5 formulations and to further study both cyclodextrin formulations.
- the final formulation for the Example 5 clinical studies consists of: 120 mg/ml of Captisol in water with the desired amount of peptide (0.5, 1.0 or 2.5 mg/ml), and HCl and NaOH for pH adjustment.
- Solubility enhancers used for Compound 1 formulation development Solubility enhancer classification
- Solubility Enhancers Solvents Cremophor EL, CMC Ethanol, DMA, Gycerin, Propylene Glycol, PEG 400, Monotioglycerol Co-solvents Polysorbate 20, Ploysorbate 80 Solubilizing.agents Argenine, HSA, Glycine, Creatinine, Glutamic acid, Lysine (acetate salt and free base), Captisol, Hydroxypropyl- ⁇ -cyclodextrin, Bulking agents Mannitol, Sorbitol, Dextrose, Lactose Dextran pH Adjustment Agents Citrate buffer, Acetate buffer, Sodium Carbonate Table 2.
- Standard dissolution methods such as mixing dry Compound 1 and dry Captisol® into water or adding Compound 1 to a prepared solution of Captisol® and water did not result in complete dissolution at the desired concentrations.
- concentrations of both Compound 1 and Captisol® were tested at various pH levels. However, the following method for producing a solution of Compound 1 in Captisol® resulted in complete dissolution at the desired concentrations.
- the current lyophilization process differs from other lyophilization processes in that the percentage of solids in the formulation is high (12%) whereas lyophilized products normally contain between 5 and 10% solids.
- the freeze drier used was an Edwards lyophilizer Lyoflex 0.6.
- the equipment IQ/OQ was performed and checked for compliance by quality assurance prior to the process development.
- Freezing - Freezing was from room temperature to -40°C within 2 hours. Shelves were held at -40°C for 3 hours.
- Drying - Drying was performed at 110 ⁇ bar pressure. Shelf temperature was increased to 20°C over 13 hours and held at that temperature for additional 13 hours.
- Drying - Drying was performed at 110 ⁇ bar pressure. Shelf temperature was increased to 20°C over 13 hours and held at that temperature for additional 13 hours (Batch 4) or 8 hours (Batch 5). Pressure was decreased to 10 ⁇ bar for additional 5 hours.
- the biological activity was monitored by inhibition of IL-2 secretion from Compound 1 reference standard (RS) specific T-cells following subcutaneous (s.c.) treatment with the lyophilized compound solution, i.e. the drug product (DP), at two concentrations.
- the results of the treatment are compared to those of treating mice with Compound 1 (RS) in phosphate buffered saline (PBS). The results are shown in the tables below and in Figure 2 .
- mice were immunized with 50 ⁇ g/mouse of Compound 1 RS.
- the immunized mice were allocated to five treatment groups as follows: placebo, 25, 50, 100 and 200 ⁇ g/mouse of Compound 1 DP (subcutaneous administration).
- Ten days post immunization and treatment LN was extracted and single cell suspension was prepared. The in-vitro secretion of IFN- ⁇ and TGF- ⁇ by the cultured cells in response to activation with several concentrations of Compound 1 RS was then measured.
- 70% ethanol was prepared from 96% ethanol by diluting with purified H 2 O.
- CFA-Compound 1 RS emulsion 500 ⁇ g/ml, 50 ⁇ g/mouse was prepared as follows:
- Treatment was by a s.c. injection of 200 ⁇ l solution.
- mice were weighed before immunization. Average mice weight: 19.01 ⁇ 0.97 gr
- the immunization was performed by injecting 100 microliters of the immunization emulsion (50 microliters into each hind footpad).
- mice were treated by s.c. injection of 200 ⁇ l from the designated Compound 1 DP or 12% captisol® treatment solutions, at the back of their neck.
- mice were sacrificed by cervical dislocation. LN were extracted from the hind legs and were transferred to a sterile petri dish containing about 5 mL RPMI. The cells were extracted by gentle squeezing of the tissue against a 200 micrometer mesh stainless steel net. The cells were collected and centrifuged at 300 G for 10 minutes at RT.
- the 10 x 10 6 cells/ml suspensions were diluted 1:2 by adding 5 ml EM-1 to 5 ml cells suspension.
- tissue culture plates were prepared. The following was added to each plate.
- 96-wells plates were prepared by applying 100 ⁇ l from the cell suspension and 100 ⁇ l from the activation solutions.
- the culture plates were incubated at 37°. C in a humidified 5% CO 2 incubator, for either 48 or 72 hrs.
- the cultured plates were centrifuged at 300 g for 10 minutes at RT. Supernatants (850 ⁇ l from each well) were transferred either to mirror plates or to tubes. The supernatant was then divided into working aliquots (two aliquots of 200 and one aliquot of 450 ⁇ l), in order to avoid repeated freeze/thawing of the samples. Each tube was labeled with the following details:
- the supernatants were stored at -20°C until used for ELISA.
- Table 10 Summary of Groups Experimental Groups: Immunization Treatment In-vitro Exp.Groups Immunization dose Sub group Article activation A1 12% Captisol® Placebo control A2 Compound 1 25 ⁇ g/M A 50 ⁇ g/mouse A3 Compound 1 50 ⁇ g/M Compound 1 RS 3.125-100 ⁇ g/ml A4 Compound 1 100 ⁇ g/M A5 Compound 1 200 ⁇ g/M Table 11-A: Final cytokine concentrations Final cytokine (pg/ml)(2.5 million cells/well) Compound 1 concentration Placebo 50 ⁇ g/M 100 ⁇ g/M 200 ⁇ g/M 3.125 ⁇ g/ml 321.3 54.1 64.5 103.9 6.25 ⁇ g/ml 238.6 81.8 116.1 126.1 12.5 ⁇ g/ml 397.1 123.1 180.9 129.0 25 ⁇ /ml 655.5 215.1 262.8 240.3 50 ⁇ g/ml 573.9 292.5 518.3 378.1 100 ⁇ g/ml 926.0 531.8 582.7 524.1
- Example 6 Optimizations of freeze drying cycle with Compound 1 and Captisol® for injection (0, 0.5, 1.0 and 2.5 mg/vial)
- Captisol ® sulfobutyl ether beta-cyclodextrin sodium
- mice were followed for anti-dsDNA antibodies and for proteinuria. When the mice were sacrificed, the intensity of ICD was determined in kidneys.
- Table 13 also shows that the beneficial effect of treatment with Compound 1 could be observed starting from the 5 th injection and it was sustained up to the 10 th injection.
- the mean levels of proteinuria in the Captisol ® control group were consistently higher than in the Compound 1 -treated groups.
- Table 13 also shows that a reduction in the intensity of ICD was observed in kidneys of both Compound 1 dose groups. There was an overall trend showing that the lower dose (25 ⁇ g/mouse) was more effective than the higher dose (50 ⁇ g/mouse) in reducing the clinical symptoms of SLE in these mice. Table 13.
- b The death of one animal with a high level of proteinuria resulted in a lower group mean.
- c p ⁇ 0.05 compared to Captisol ® -treated control mice; Mann-Whitney).
- Figure 6 shows representative sections of one kidney from each treatment group.
- the top row sections are from a Captisol ® -treated mouse, the mid-row sections are from a mouse treated with 50 ⁇ g/mouse Compound 1 and the bottom row sections are from a mouse treated with 25 ⁇ g/mouse Compound 1. It can be seen that the intensity of immune complex deposits observed in kidney sections of mice treated with Compound 1 (dissolved in Captisol ® ) at either dose level was much lower than that observed in the control group.
- SLE patients Thirty-six (36) subjects participated in the study. To be eligible for inclusion in the study, SLE patients must have fulfilled at least four criteria used for the diagnosis of lupus by the American College of Rheumatology. Patients must also have had stable, mild/moderate disease and score less than or equal to 10 on the SLE Disease Activity Index, SLEDAI.
- a standard battery of safety tests including blood and urine collection for laboratory tests, was performed at screening, during the day of dosing at 24 hours post-dose and at 2, 4 and 8 weeks following dosing. Prior to dosing, and on scheduled follow-up visits, blood samples were withdrawn for SLE-related immunological tests, anti-Compound 1 antibodies and PBL proliferation assay. The following immunology tests were performed:
- Compound 1 in captisol®), Placebo, Water for Injection-Ampoules, Dose and Mode of Administration:
- Vials of Compound 1 in Captisol ® 120mg/vial were injected subcutaneously as a single dose per subject in the following dosages:
- Placebo for Compound 1 120 mg Captisol ® /vial (identical in appearance to vials of Compound 1 in Captisol ® ).
- Blood samples serum and whole blood for safety laboratory tests were withdrawn at Screening, Dosing Day (pre-dose), Day 2 (post dose), at Weeks 2, 4 and 8 (Termination visit). Blood samples for immunological tests were withdrawn at: Screening, Dosing Day (pre-dose) and at Weeks 4 and 8.
- Eligible subjects for this study were SLE patients who fulfilled at least four diagnostic criteria of the American College of Rheumatology (ACR). Their disease condition had to be stable, mild to moderate with a score equal to or less than 10 on the SLE disease activity index, year 2000 updated (SLEDAI 2K).
- SLE patients who reported unstable or severe asthma, stroke, acute myocardial infarction, unstable angina, cerebral hemorrhage and pulmonary embolism during the six months prior to study screening.
- SLE patients wno had any clinically significant or unstable medical or surgical conditions, diabetes mellitus, liver disease (cirrhosis, active hepatitis, portal hypertension, and/or ascites), clinically significant hypertension, a medical history of any malignancy, dialysis, or chronic obstructive pulmonary disease (COPD) were also excluded from study participation.
- COPD chronic obstructive pulmonary disease
- prednisone 30mg/day or greater or an equivalent dose of another corticosteroid
- intravenous corticosteroids or an equivalent dose of another corticosteroid
- IgG intravenous immunoglobulin G
- oral anticoagulants e.g. azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, methothrexate, tacrolimus.
- cytotoxic agents e.g. azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, methothrexate, tacrolimus.
- corticosteroids more than ⁇ 10 mg/day prednisone, or an equivalent dose of another corticosteroid
- anti-malarials during the last 3 months prior to screening were excluded from the study.
- Drug-related immunological responses were followed by using the PBL proliferation assay and anti-Compound 1 antibodies assay at the Dosing Day and at follow-up visits including Termination visit.
- SLE disease activity index score year 2000 updated (SLEDAI 2K) was assessed at Screening, during the hospitalization and at follow-up visits including Termination visit.
- Descriptive statistics for vital signs including number of observations, mean, standard deviation, median, minimum and maximum values were determined for Screening, Day 1 (pre and post dose, and at each time point) Day 2, Weeks 2, 4 and 8 are tabulated by the assigned treatment. Changes from baseline to each time point/visit is presented in by visit and treatment assignment.
- Descriptive statistics including mean, standard deviation, median, minimum and maximum values of SLEDAI 2K are presented.
- the peripheral blood lymphocytes (PBL) assay showed that 50 % of the subjects (18) were classified as responders (SI>2) with similar distribution in all treatment groups.
- the T cell response was relatively low and no association between Compound 1 treatment dose or concentration used in the assay and responder non-responder status could be detected, taking into consideration that only a single SC dose of the study drug was administered. Also, no indication of increased incidence of responder status over time was observed.
- the tetanus toxoid (TTX) assay that serves as a safety control shows that the response to TTX was preserved throughout the study period in all treatment groups indicating that Compound 1 in captisol® did not change the immunological response to TTX recall antigen.
- the immunological findings are the result of the administration of only a single dose of the study drug Compound 1.
- This study is being performed in order to evaluate the safety and tolerability of repeated Compound 1 sc administration to SLE subjects.
- the study's secondary objective is to evaluate immunological responses following repeated sc administration of Compound 1 in Captisol® in SLE subjects.
- Compound 1 is given in doses of 0.5, 1.0 or 2.5 mg in Captisol ® .
- the investigational product is administered every other day (excluding weekends) for a total of 12 sc injections, i.e. 3 doses a week for 4 weeks.
- Subjects are monitored on planned visits scheduled at 2, 4, 8 and 12 weeks after start of dosing. Safety and tolerability are evaluated using tests similar to those described in the Phase Ia Clinical Study above.
- Example 10 Detection of antibodies against peptides Ia, IIa and IIIa, and anti-1616 Id antibodies in the sera of SLE patients and healthy controls
- Detection of the antibodies was conducted on plates that were coated with 10 ⁇ g/ml of peptides Ia, IIa, IIIa, p195-212 or mAb 5G12, in PBS for 2 hr, washed and blocked with 1% ovalbumin in PBS for an additional 2 hr.
- ELISA was continued as described after blockage in Example 2 of PCT International Publication No. 96/30057 , using goat anti-human IgG polyclonal antibody conjugated to peroxidase.
- PBL Peripheral blood lymphocytes
- Example 12 Production of IL-2 by PBL of SLE patients and healthy controls in the presence of human mAb 16/6 Id and peptides
- PBL were isolated from blood of SLE patients or healthy controls using ficol gradient, and were incubated as in Example 11. A sample of 50 ⁇ l was removed 24 hr after the assay was started, and incubated in the presence of IL-2 sensitive cells (CTLD) for 24 hr, after which 3 H-thymidine was added for 16 hr, and the plates were harvested and counted on a beta counter.
- CTL IL-2 sensitive cells
- the human hCDR1 (SEQ ID NO: 6) and hCDR3 (SEQ ID NO: 7) are shown below.
- peptides were prepared by methods well-known in the art, for example, by chemical solid phase or solution phase synthesis using an automated synthesizer by using the manufacturer's protocols for t-butyloxycarbonyl (t-Boc), fluorenylmethoxycarbonyl (Fmoc) or other alpha-amino acid protecting group procedure essentially as described (see, for example, Peptides: Synthesis, Structure and Applications, ed. By B. Gutte, Academic Press, 1995 ; Peptide Synthesis Protocols, ed. by M. Pennington and B. Dunn, Humana Press,1994 ; Schnolzer M. et al., In situ neutralization in Bocchemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40: 180-193,1992 ).
- Peptides hCDR1 and hCDR3 inhibit the proliferative response of PBL of SLE patients to the human16/6Id mAb.
- PBL of 62 consecutive SLE patients were cultured in the presence of the human 16/6 Id and their proliferative responses and ability to secrete IL-2 were determined.
- the frequency of responders in the group of SLE patients was lower than that observed in the group of healthy donors that was tested as control.
- PBL of 21 out of a total of 36 (58%) healthy donors responded by proliferation to the 16/6 Id.
- the extent of proliferation (SI levels) was similar for the SLE patients and for the healthy controls who responded to the 16/6 Id.
- the optimal response to the 16/6 Id of PBL of the control donors was observed at higher concentrations of 16/6 Id as compared to the SLE patients.
- Antinuclear antibodies (ANA) and anti-dsDNA antibodies were determined by Hep2 cells and Crithidia luciliae, respectively.
- Anti-phospholipid antibodies (APLA) were defined as activity in one or more of the following assays: false positive VDRL, lupus anti-coagulant (LAC) or ELISA for anticardiolipin antibodies.
- the anti-malarial agent, hydroxychloroquine was used at a dose of 200-400 mg/day ; Steroid treatment was defined as a daily dose: 5mg of prednisone ; cytotoxic agents used were cyclophosphamide (0.75-1.0g/m 2 ; monthly) or azathioprine (100-150 mg/day).
- PBL (2x10 5 /well) of SLE patients were stimulated in vitro in triplicates with different concentrations (0.1-20 ⁇ g/well ) of the human 16/6Id mAb in the absence or presence of the peptides hCDR1 and hCDR3 (either 50 or 100 ⁇ g/well).
- 3 H-thymidine 0.5 ⁇ Ci of 5 Ci/mmol was added to each well for additional 18 hours of incubation. Cells were then harvested and radioactivity was counted using a ⁇ -counter.
- Results were expressed as mean counts per minute (cpm) of triplicate cultures. Stimulation indices (the ratio of mean cpm at the optimal concentration of 16/6Id to mean cpm without 16/6Id) were then calculated. A stimulation index (SI) ⁇ 2 was considered positive.
- Table 17 shows the results of these experiments. Inhibition of above 50% of the proliferative capacity was considered positive.
- the Table represents the highest positive inhibition capacity for each peptide. It can be seen that the human hCDR1 and hCDR3 inhibited the proliferation of PBL of 16/19 (84.2%) and 15/19 (78.9%), respectively, of the 19 responders tested. Both peptides inhibited the proliferation of PBL of 18/19(95%) of responders tested. It can also be seen in the Table that the magnitudes of inhibitions were similar for both peptides.
- peptides based on CDR1 and CDR3 of the human 16/6Id mAb are efficient inhibitors of the proliferation of PBL of SLE patients to the human 16/6Id mAb.
- Table 17 Inhibition of proliferation of PBL of SLE patients by peptides hCDR1 and hCDR3. Number Percent Inhibition hCDR1 hCDR3 1. 62 ⁇ 50 2. 70 75 3. 69 ⁇ 50 4. ⁇ 50 ⁇ 50 5. 88.5 87.5 6. 80 80 7. 76 70.4 8. 58 56 9. 69.5 65 10. 68.2 71.8 11. ⁇ 50 72 12. 82 86 13. 63 64 14. 56 74 15. 63 69 16. ⁇ 50 68 17. 70.5 77.8 18. 51.5 ⁇ 50 19. 63 60.8 Mean ⁇ SD 68.12 ⁇ 9.57 71.82 ⁇ 8.44
- hCDR1 or hCDR3 were added to cultures of PBL of SLE patients that were stimulated with the mitogen phytohemagglutinin (PHA,2 ⁇ g/ml). The results of such an experiment performed with PBL of one SLE patient is shown in Figure 9 .
- the peptides hCDR1 and hCDR3 could not inhibit the proliferative responses (expressed in cpm) of the PBL to the mitogen PHA and the proliferative responses were similarly high in the absence (black column) or presence of either hCDR1 or hCDR3.
- hCDR peptides are capable of inhibiting IL-2 secretion by PBL of SLE patients following stimulation with the human 16/6Id mAb. Such inhibition might also suggest that the human CDR-based peptides inhibit the proliferative responses to the 16/6Id mAb at least partially by down-regulating IL-2 secretion.
- PBL of SLE patients were incubated with the human 16/61d mAb in the absence or presence of the peptides hCDR1 or hCDR1 Supernatants of the cultures were collected following 48 hours of incubation. Assays to determine levels of IL-2 in the supernatants were performed using the CTLL IL-2 dependent line.
- TGF- ⁇ was determined by ELISA according to the manufacturer's instructions. Briefly, Maxisorb plates (Nunc) were coated with recombinant human TGF ⁇ sRII/Fc chimera (R & D Systems) diluted in PBS (100 ng/ml). After blocking, cell supernatants were added. After 18 hours incubation the detecting biotinylated anti-human TGF- ⁇ antibody (R & D Systems) was added. The substrate solution used was the TMB Colour Reagent (Helix Diagnostics) and enzyme activity was evaluated by the MRX ELISA reader using the 570 nm and 630 nm filters. The results are summarized in Table 19.
- MMP-9 and MMP-2 we determined the levels of MMP-9 and MMP-2 in sera of 40 patients with SLE and we demonstrate that MMP-9 but not MMP-2 activity is significantly elevated in sera of SLE patients compared to healthy controls.
- High MMP-9 activity correlated with the presence of discoid rash, Raynaud phenomenon, pneumonitis, mucosal ulcers and the presence of anti phospholipid antibodies (APLA).
- APLA anti phospholipid antibodies
- elevated levels of MMP-9 correlated with SLE' activity in the group of male patients.
- MMP-2 and MMP - 9 Measurement of MMP-2 and MMP - 9 by activit assay kits. Activities of MMP-2 and MMP-9 were measured by specific Biotrak MMP-2 or MMP-9 activity assay kits (Amersham Pharmacia Biotech UK Limited, UK) according to the manufacturer's instructions. Sera were diluted 1:100 and 1:32 for the determination of MMP-2 and MMP-9 activities, respectively. The appropriate standards were added in each assay. In order to measure the total content of the MMPs, activation of the pro form of the MMPs was performed using p-aminophenylmercuric acetate (APMA).
- APMA p-aminophenylmercuric acetate
- MMP-2 and MMP-9 activities were tested by gelatin zymography.
- a 5 ⁇ l sample of serum was separated by an 8% SDS-PAGE gel polymerized with 1 mg/ml gelatin. Gels were washed once for 30 min in 2.5% Triton X-100 to remove the SDS, and once for 30 min in the reaction buffer containing 50 mM Tris-HCI, 200 mM NaCl, 10 mM CaCl 2 and 0.02%(w/v) Brij 35 (pH 7.5). The reaction buffer was changed to a fresh one, and the gels were incubated at37°C for 24 h. Gelatinolytic activity was visualized by staining the gels with 0.5% Coomassie brilliant blue and was quantified by densitometry.
- MMP-9 was shown to be involved in several autoimmune diseases as well as in animal models of SLE.
- sera of 40 SLE patients and of 25 healthy controls by gel zymography, in which both MMP-9 and MMP-2 activities can be visualized.
- a representative gel is shown in Figure 14 .
- levels of MMP-9 are elevated in the sera of SLE patients when compared to healthy controls.
- MMP-9 LEVELS (%) High Normal Number of Patients (%) 40(100) 27 (68) 13 (32) Photosensistivity 13 8 (62) 5(38) Mucosal ulcers 9 8(89) 1 (11) Malar rash 9 7(78) 2(22) Discoid rash 5 5(100) 0(0) Raynaud phenomenon 8 8(100) 0(0) Vasculitis 18 14 (78) 4 (22) Arthritis 31 21 (68) 10 (32) Serositis 9 7(78) 2(22) Pneumonitis 4 4(100) 0(0) Neurological disorders 4 4 (100) 0(0) Renal disorder 16 11(69) 5(31) Hematological Disorders 29 18 (62) 11 (38) ANA 40 27 (68) 13 (32) ⁇ ds-
- Anti-nuclear antibodies ANA
- anti-ds DNA antibodies were determined by using Hep2 cells and Crithidia lucilie , respectively.
- Antiphospholipid antibodies were defined as reactivity with one or more of the following assays: false positive VDR, lupus anti-coagulant (LAC) or ELISA for anticardiolipin antibodies.
- the anti-malarial agent hydroxychloroquine was used at dose of 200-400 mg/day. Steroid treatment was defined as a daily dose ⁇ mg of prednisone. Cytotoxic agents used were cyclophosphamide (0.5-1g/m 2 monthly) or azathioprine (100-150 mg/day).
- MMP-9 The present study demonstrates for the first time the involvement of MMP-9 in human SLE.
- MMP-9 the activity of MMP-9, but not MMP-2, is significantly elevated in sera of 68% of SLE patients compared with healthy controls.
- High MMP-9 levels correlated with Raynaud phenomenon, pneumonitis, neurological disorders, discoid rash and the presence of APLA. Changes in MMP-9 activity were observed in serum of the same patient at different periods of the disease.
- MMP-9 activity levels did not correlate with disease activity index (SLEDAI, BILAG) in female patients, but correlated with SLE activity in the group of male patients.
- SLEDAI disease activity index
- MMP-3 MMP-3 was suggested in the pathogenesis of SLE, since it was significantly increased in sera of patients with SLE ( Kotajima, L. et al., Clin. Exp. Rheum. 16: 409-415 (1998 )).
- the MMP-3 transcript was shown to increase significantly with the progression of nephritis in (NZB x NZW) F1 mice ( Nakamura, T. et al., Clin. Sci. 85:295-301 (1993 )).
- MMP-9 has been shown to be secreted by peripheral blood cells such as T cells, neutrophils, and macrophages (for review, see Goetzl, E. J. et al., J. Immunol. 156: 1-4 (1996 )).
- peripheral blood cells such as T cells, neutrophils, and macrophages
- MMP-9 activity levels may suggest that MMP-9 was not secreted by peripheral blood immune cells but rather, by SLE-affected organs like kidneys or lungs/pleura.
- SLE-affected organs like kidneys or lungs/pleura.
- All SLE patients with pneumonitis exhibited high MMP-9 activity levels may suggest the diseased lung as a source of high MMP-9 levels.
- cytotoxic treatment which represents the severity of SLE-related organ impairment
- high levels of MMP-9 in the sera may also support the notion that the diseased organs are the source of MMP-9 activity in SLE patients. Nevertheless, the possibility still exists that less peripheral blood lymphocytes secreted higher activity levels of MMP-9.
- TNF- ⁇ and IL-1 were shown to play an important role in the pathogenesis of SLE both in the human disease ( Dean G.S. et al., Ann Rheum Dis 59: 243-51 (2000 )) and in murine models ( Segal R. et al., J Immunol 158: 3009-16 (1997 ); Theofilopoulos A.N. et al., Ann Rheum Dis 58 (suppl): 149-55 (1999 ); Eilat et al., 2001). It has been shown in several systems that these cytokines induce MMP-9 production ( Guedez, L. et al., Crit. Rev.
- MMP-9 that are secreted spontaneously by peripheral blood monocytes of healthy individuals, were upregulated upon exposureto TNF- ⁇ and IL-1 ⁇ ( Saren P. et al., J Immunol 157: 4159-65 (1996 )).
- MMPs of both T cells and macrophages facilitate secretion of TNF- ⁇ by cleavage of the membrane-bound form ( Gearing A.J.H. et al., Nature 370:555-7 (1994 )).
- MMP-9 might play a role in the pathogenesis of SLE, and that measurement of plasma/serum activity levels of this metalloproteinase may provide important information when monitoring patients treated with drugs that interfere with MMP-9 activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Description
- Systemic lupus erythematosus (SLE), or lupus, is a debilitating autoimmune disease characterized by the presence of an array of autoantibodies, including antibodies to dsDNA, to nuclear antigens and to ribonucleoproteins. SLE affects approximately 1 in 2000 individuals (U.S. 1 in 700 women). The disease primarily affects young women, with a female-to male ratio of approximately 9:1.
- Systemic lupus can affect almost any organ or system of the body. Systemic lupus may include periods in which few, if any, symptoms are evident ("remission") and other times when the disease becomes more active ("flare"). Most often when people mention "lupus," they are referring to the systemic form of the disease.
- Corticosteroids are the mainstay in treating systemic autoimmune disorders. Life threatening, severely disabling manifestations of SLE are treated with high doses of glucocorticoids (1-2 mg/kg/day). Undesirable effects of chronic glucocorticoids include an array of prominent adverse effects such as cushingoid habitus, central obesity, hypertension, infection, capillary fragility, hirsutism, accelerated osteoporosis, cataracts, diabetes mellitus, myopathy and psychosis. In addition to corticosteroid toxicity, patient compliance to a dosage regimen also poses a serious problem.
- Cytotoxic agents are also used for controlling active disease, reducing the rate of disease flares, and reducing steroid requirements. Undesirable side effects of the latter include bone marrow depression, increased infections with opportunistic organisms, irreversible ovarian failure, alopecia and increased risk of malignancy.
- SLE is an inflammatory disease for which to date there is no definitive treatment or cure. The disease results in acute and chronic complications. The only treatments available are palliative, aimed at relieving acute symptoms and preventing chronic complications, often with profound side effects. There is therefore an unmet need in this field, and both physicians and patients would welcome new treatments which could potentially eliminate or reduce the unwanted manifestations of the disease.
- Despite the extensive research on the mechanisms underlying the induction of SLE, the information on the etiology of the disease is very limited. Studies on SLE have been performed until recently using peripheral blood lymphocytes (PBL) of patients at different clinical stages and under various treatment protocols. Alternatively, murine strains that develop spontaneous SLE-like disease were investigated as a model for SLE. This kind of analysis led to incomplete and confusing interpretations of the role of various immunological and non-immunological factors in either inducing or sustaining the disease, mainly due to the heterogeneity of patients on one hand and the inability to control the induction phase of the disease in murine SLE strains on the other hand.
- Several years ago, an animal model of SLE was established. This model, based on the concept of the idiotypic network, developed a wide spectrum of lupus-related autoantibodies and clinical manifestations (Mendlovic, S. et al. Proc. Natl. Acad Sci. USA 85: 2260 (1988)). The induction was carried out by the immunization of mouse strains that do not develop any spontaneous autoimmune disorders, with a human anti-DNA monoclonal antibody (mAb) which bears a common idiotype termed 16/6 Id (Shoenfeld, Y. et al., J. Exp. Med. 158: 718 (1983)).
- The
human mAB 16/6 is an anti-DNA antibody originally of the IgM isotype and switched in culture to IgG1. The mAB was derived from a patient and expresses a common idiotype, the 16/6 Id (Shoenfeld et al., 1983; Mendlovic et al., 1988). The hybridoma cells secreting this mAB are routinely grown in culture, and the antibody is isolated from culture supernatants using an affinity column of Protein G coupled to Sepharose™. The human 16/6 anti-DNA mAB (IgG1/κ) was described in Shoenfeld, Y. et al., J. Clin. Invest. 70: 205-208 (1982) and in Waisman, A. et al., Int. Immunol. 7: 689-696 (1995). - Following immunization, the mice produced antibodies specific to the 16/6 Id, antibodies that bear the 16/6 Id and antibodies directed against different nuclear antigens (dsDNA, ssDNA, Sm, ribonucleoprotein (RNP), Ro, La and others). The serological findings were associated with leukopenia, elevated erythrocyte sedimentation rate, proteinuria, abundance of immune complexes in the kidneys and sclerosis of the glomeruli (Mendlovic et al., 1988), which are typical manifestations of SLE. It was further shown that the experimental disease could be induced by a murine anti-16/6 Id mAb (Mendlovic, S. et al., Eur. J. Immunol. 19: 729, (1989)) and by the mouse anti-anti 16/6 Id (16/6 Id+) mAb (Waisman, A. et al., Internatl. Immunol. 5:1293 (1993); Waisman, A. and Mozes, E. Eur. J. Immunol. 23: 1566, (1993)). The induction of the disease is genetically controlled, and thus is strain dependent (Mendlovic, S. et al., Immunology 69: 228 (1990)). This unique model for the induction of experimental SLE provides the appropriate tools to clearly dissect the different steps and the linked immune parameters involved in the induction and development of SLE.
- SLE is a systemic autoimmune disease characterized by the formation of auto antibodies against self-antigens, such as DNA, Sm, Ro, La, RNP, cardiolipin and histones. The etiology of SLE is unknown, and understanding the mechanism by which these self-antibodies arise provided insight. Monoclonal autoantibodies that were capable of eliciting antibodies that bear the 16/6 Id or react with it were found to be pathogenic and thus capable of inducing experimental SLE (Fricke, H. et al., Internatl. Immunol. 2: 225 (1990); Sthoeger, Z.M. et al., J. Clin. Immunol. 13: 127 (1993)). The variable (V) regions of nine autoantibodies that bind either DNA or HeLa nuclear extract (NE), isolated from the C3H.SW mice with experimental SLE, were sequenced (Waisman and Mozes, 1993). Monoclonal antibodies with different specificity were analyzed in an attempt to determine the connections between the different autoantibodies. Three mAb were found to bind DNA, and were shown to exhibit sequence characteristics of pathogenic anti-DNA antibodies. One of these mAb, designated 2C4C2, was shown to use a heavy (H) chain V region gene (VH) identical to the VH of anti-DNA mAb isolated from other lupus-prone mice, namely (NZB xNZW)F1. The light (L) chain V region gene (VL) of mAb 2C4C2 is 98% homologous to the VL of another anti-DNA mAb, also isolated from (NZB xNZW)F1 mice. The other two anti-DNA mAb, designated 5G12-4 and 5G12-6, share 93% of their VH sequences with that of mAb 2C4C2. Six mAb bound proteins of HeLa NE. The nine mAb use a total of five VH and four VL germ-line genes, demonstrating that the autoantibodies induced in mice with experimental SLE do not originate from one B cell clone. Three of the nine VH and VL were identical in sequence to germ-line genes, while at least three others had somatic mutations. The latter suggests that these autoantibodies arise in mice by both usage of existing (pre-immune) B cells, and through anantigen-driven process. Furthermore, it appears that autoantibodies found in mice with experimental SLE use genetic elements similar to those used by mAb that were isolated from mouse strains which develop lupus spontaneously.
- T cells play an important role in the induction and development of experimental SLE. Thus, T cell lines and clones specific to the 16/6 Id were shown to induce experimental SLE in syngeneic recipients similarly to the 16/6 antibody. Therefore, following the inoculation of the activated cells of the lines, the mice developed both the serology and the renal damage which is typical to SLE (Fricke, H. et al., Immunology 73: 421 (1991)). Furthermore, a 16/6 Id specific T cell line of C3H.SW origin induced SLE in C57BL/6 mice that were shown to be resistant to the induction of the disease following injections with either the 16/6 Id or the anti-16/6Id mAb (Mendlovic et al., 1990).
- In an attempt to identify the pathogenic region of the 16/6 Id, (Fab')2 fragments were prepared of the 16/6 Id mAb and were found to retain the specificity and pathogenic capacity of the whole 16/6 Id molecule (Ruiz, P.J. et al., Immun. Let. 41: 79 (1994)).
- The mAb 5G12 that was isolated from mice with experimental SLE and was shown to bind DNA and bear the 16/6. Id, is capable of inducing experimental SLE in mice (Waisman, A. et al., Internatl. Immunol. 5:1293 (1993)). T cells that react specifically to mAb by proliferation, are probably reacting to peptides representing sequences from their complementarity-determining regions (CDR). It is very likely that the T cells recognize the V regions of the above antibodies since they do not react with other antibodies that carry the same constant region but have different specificities. Within the variable region, the regions with the highest probability to be recognized are the CDR, since those are the regions that differ the most between the various antibodies. The CDR regions of the VH sequences of the nine pathogenic murine mAb mentioned above that induce SLE in mice, are boxed in
Fig. 1 of Waisman and Mozes, 1993, in which the complete nucleotide and deduced amino acid sequences for the VH of the nine mAb are presented. - In experimental SLE models - Balb/c mice and SLE-prone mice, i.e. (NZBxNZW)F1 mice - treatment with either mCDR based-peptides or
Compound 1 significantly reduced the SLE related findings, notably immune complex deposits (ICD) in the kidney, proteinuria and leukopenia. The treatment had no effect on the 16/6 Id specific antibody response (Waisman, A., et al. "Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti -DNA monoclonal antibodies." Proc. Natl. Acad. Sci. U.S.A. (1997), 94(4): 620; Eilat, E., et al., "Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3- based peptides of pathogenic autoantibody" J. Clin. Immunol. (2000), 20: 268; Eilat, E., et al., "The mechanism by which a peptide based on complementarity determining region-1 of pathogenic anti-DNA antibody ameliorates experimental SLE" (2001), Proc.Natl.Acad. Sci. U.S.A. 98: 1148). - Human CDR1,
Compound 1, shown inFigure 1 , is a synthetic peptide of 19 amino acids based on the complementarity-determining region 1 (CDR1) of the human anti-dsDNA mAb denoted 16/6 Id (Waisman, A., et al. "Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti-DNA monoclonal antibodies." Proc. Natl. Acad. Sci. U.S.A. (1997), 94(4): 4620-4625). -
WO02/067848 A2 -
WO9630057 A1 - These peptides, like many peptides, are not very soluble. Therefore, formulations that improve the solubility of the peptides are provided herein.
- The subject invention provides a pharmaceutical composition comprising:
- an aqueous carrier;
- from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of
- a peptide comprising consecutive amino acids having the sequence
- (i) TGYYX1X2X3X4XSQSPEKSLEWIG (SEQ ID NO:11) wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala;
- (ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;
- (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;
- (iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;
- (v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;
- (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;
- (viii) FSGYYWS (SEQ ID NO:8);
- (ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or
- (x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10),
- wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and
- wherein the composition has a pH between 4 and 9.
- a peptide comprising consecutive amino acids having the sequence
- The subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject any of the pharmaceutical compositions of the invention in an amount effective to alleviate the symptoms of SLE in the human subject.
-
-
Figure 1 . Human CDR1 (Compound 1) as acetate salt - showing the molecular and structural formulas of hCDR1, the amino acid sequence, and physical parameters -
Figure 2 . IL-2 Secretion from cells taken from mice treated withCompound 1 and Captisol® solution after the cells were subsequently activated with a solution ofCompound 1 in PBS.- -■- Compound 1 (RS) 50µg/mouse
- -▲- Compound 1 (RS) 200µg/mouse
- -□- DP 50µg/mouse
- -Δ- DP 200µg/mouse
- -●- Captisol® ampulized
-
Figure 3 . IFN-γ Secretion from cells taken from mice treated withCompound 1 solution after the cells were subsequently activated with a solution ofcompound 1 in EM-1 (2.5 x 106 cells/well).- -◆- Placebo
- -●-
Compound 1 50 µg/mouse (treatment dose) - -Δ-
Compound 1 100 µg/mouse (treatment dose) - -X-
Compound 1 200 µg/mouse (treatment dose)
-
Figure 4 . IFN-γ Secretion from cells taken from mice treated withCompound 1 solution after the cells were subsequently activated with a solution ofcompound 1 in EM-1 (5 x 106 cells/well).- -◆- Placebo
- -□-
Compound 1 25 µg/mouse - -Δ-
Compound 1 50 µg/mouse - -X-
Compound 1 100 µg/mouse - -*-
Compound 1 200 µg/mouse
-
Figure 5 . Anti-dsDNA antibodies in (NZBxNZW)F1 mice after 10 injections withCompound 1 in Captisol® [OD=Optical Density; Compound 1 (C)=Compound 1 dissolved in Captisol®]- -□- Placebo
- -◊-
Compound 1 50 µg/mouse - -○-
Compound 1 25 µg/mouse
-
Figure 6 . Kidney sections from (NZBxNZW)F1 mice showing intensity of Immune Complex Deposits. The top row sections are from a Captisol®-treated mouse, the mid-row sections are from a mouse treated with 50 µg/mouse Compound 1 and the bottom row sections are from a mouse treated with 25 µg/mouse Compound 1. Magnification: Left: x100, Right: x400. FITC immunohistology. -
Figure 7 . Antibody titers in sera of SLE patients and healthy human controls by testing their sera for the ability to bind the peptides Ia, IIa and IIIa, or mAb 5G12 or a control peptide. -
Figure 8 . Concentrations of the human anti-DNA 16/6 Id mAb required for optimal stimulation of PBL of SLE patients and of healthy controls. PBL were stimulated with various concentrations (0.1-40 µg/well) of the 16/6 Id mAb. The concentration yielding the highest stimulation index was defined as optimal for triggering a proliferative response. -
Figure 9 . Proliferation of PBL from one SLE patient stimulated with the mitogen phytohemagglutinin (PHA) in the absence or presence of hCDR1 or hCDR3. -
Figure 10 . Proliferation of PBL from one SLE patient stimulated with human 16/6I mAb in the absence or presence of the human peptides hCDR1 or hCDR3 or the murine peptide mCDR3. -
Figure 11 . Proliferation of PBL from one SLE patient stimulated withHuman 16/6I mAb in the absence or presence of the human peptides hCDR1 or hCDR3 or the murine reversed peptides revmCDR1 and revmCDR3. -
Figure 12 . Inhibition of IL-2 secretion in PBL of SLE patients triggered by the human 16/6Id mAb in the absence or presence of hCDR1 or hCDR3. -
Figure 13 . Up-regulation of TGF-β secretion in the PBL of one representative SLE patient stimulated with the human 16/6Id mAb in the absence or presence of hCDR1 or hCDR3. -
Figure 14 . Representative gel showing activity of MMP-2 and MMP-9 in sera of SLE patients and healthy controls. Sera (5 µl) of 40 individual SLE patients and 25 healthy controls were analysed for their MMP-2 or MMP-9 activities by gel zymography. The figure shows representative results with serum samples of the two groups. -
Figure 15 . Graph showing quantitative analysis of MMP-2 and MMP-9 activities in sera of SLE patients (dark columns) and healthy controls (white columns). Thirty-six serum samples of SLE patients and 15 serum samples of healthy controls were tested for MMP-2 or MMP-9 activity using specific activity assay kits. Results are expressed as the mean ± s.e.m. *P = 0.0302. -
Figures 16A-B. Graphs showing MMP-9 activity levels and disease activity indices (SLEDAI) in patients with SLE. Thirty-five serum samples from 8 male (Fig. 16A ) and 27 female (Fig. 16B ) SLE patients were tested for MMP-9 activity by a specific activity assay kit. The distribution of MMP-9 activity according to the SLEDAI of the patients is presented. The dashed line represents the activity of MMP-9 in healthy controls. -
Figures 17A-B. Graphs showing pattern of MMP-2 (white circles) and MMP-9 (black circles) activities in sera of two SLE patients sampled during 4-6 years of disease. The sera were tested for MMP-2 or MMP-9 activities by specific activity assay kits. The assays were performed in duplicate. - The subject invention provides a pharmaceutical composition comprising:
- an aqueous carrier;
- from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide comprising consecutive amino acids having the sequence
- (i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11)
wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala; - (ii) EINPSTGGX6X7X5X9X10X11X12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;
- (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;
- (iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;
- (v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;
- (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;
- (viii) FSGYYWS (SEQ ID NO:8);
- (ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or
- (x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10),
- (i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11)
- wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and
- wherein the composition has a pH between 4 and 9.
- In one embodiment, at least 0.5 mg/ml of the composition is the pharmaceutically acceptable salt of the peptide.
- In another embodiment, the peptide has a sequence selected from the group consisting of:
- NH2- Thr Gly Tyr Tyr Met Gin Trp Val Lys Gin Ser Pro Glu Lys Ser Leu Glu-Trp Ile Gly-COOH (SEQ ID NO:1);
- NH2- Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr-COOH (SEQ ID NO:2);
- NH2- Tyr Tyr Cys Ala Arg Phe Leu Trp Glu Pro Tyr Ala Met Asp Tyr Trp Gly Gln Gly Ser-COOH (SEQ ID NO:3);
- NH2- Gly Tyr Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly-COOH (SEQ ID NO:4);
- NH2- Tyr Tyr Cys Ala Arg Ser Gly Arg Tyr Gly Asn Tyr Trp Gly Gln Thr Leu -COOH (SEQ ID NO:5);
- NH2 - Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:6);
- NH2- Phe Ser Gly Tyr Tyr Trp Ser-COOH (SEQ ID NO: 8);
- NH2- Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Lys Thr Ser Leu Lys Ser-COOH (SEQ ID NO:9); and
- NH2- Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp Tyr Tyr Tyr Gly Met Asp Val-COOH (SEQ ID NO:10).
- In one embodiment, the peptide comprises consecutive amino acids having the sequence
- X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16)
- wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser.
- In one embodiment, the substituted β-cyclodextrin is a hydroxypropyl, a sulfobutyl ether, or asulfopropyl ether substituted β-cyclodextrin.
- In another embodiment, the substituted β-cyclodextrin is a substituted sulfobutyl ether β-cyclodextrin.
- In a further embodiment of any of the above compositions, the concentration of peptide in solution is at least 1 mg/ml.
- In a further embodiment, the concentration of peptide in solution is at least 2.5 mg/ml.
- In one embodiment, the concentration of the salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 0.5 mg/ml to 2.5 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 2.5 mg/ml to 5 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 5 mg/ml to 7 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 7 mg/ml to 8.5 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 8.5 mg/ml to 10 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 9 mg/ml to 10 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 10 mg/ml to 15 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is from 15 mg/ml to 20 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is 1.0 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is 2.5 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is 5 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is 10 mg/ml.
- In another embodiment, the concentration of the salt of the peptide is 15 mg/ml.
- In another embodiment, the concentration of the salt is from 0.1 mg/ml to 0.5 mg/ml.
- In another embodiment, the concentration of the salt is from 0.1 mg/ml to 0.2 mg/ml.
- In another embodiment, the concentration of the salt is from 0.2 mg/ml to 0.3 mg/ml.
- In another embodiment, the concentration of the salt is from 0.3 mg/ml to 0.4 mg/ml.
- In another embodiment, the concentration of the salt is from 0.4 mg/ml to 0.5 mg/ml.
- In a further embodiment, the composition has a pH between 6.5 and 8.5.
- In a further embodiment, the composition has a pH between 7.5 and 8.5.
- In a further embodiment, the composition has a pH between 4 and 5.
- In a further embodiment, the composition has a pH between 5 and 6.
- In a further embodiment, the composition has a pH between 6 and 7.
- In a further embodiment, the composition has a pH between 7 and 8.
- In a further embodiment, the composition has a pH between 8 and 9.
- In another embodiment of any of the above pharmaceutical compositions, the pharmaceutically acceptable salt is an acetate salt.
- In a further embodiment, the pharmaceutically acceptable salt is an acetate salt, and the substituted β-cyclodextrin is hepta-(sulfobutyl ether)-β-cyclodextrin.
- In another embodiment, the composition further comprises a pharmaceutically acceptable buffer in an amount and of a type suitable to make the pH of the pharmaceutical composition in the range of 4-9. The buffer may be acetate buffer, citrate buffer, or sodium carbonate.
- The subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject any of the above pharmaceutical compositions in an amount effective to alleviate the symptoms of the SLE in the human subject.
- The subject invention also provides any of the above pharmaceutical compositions for use in treating SLE in a human subject.
- The subject invention also provides a process for manufacturing any of the above pharmaceutical compositions comprising the steps of:
- a) preparing a solution of substituted β-cyclodextrin in an aqueous carrier at a predetermined concentration;
- b) adding a predetermined amount of a pharmaceutically acceptable salt of
- a peptide comprising amino acids having the sequence
- (i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11) wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala;
- (ii) EINPSTGGX6X7X9X9Xl0XnX12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;
- (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;
- (iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;
- (v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala for Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;
- (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;
- (viii) FSGYYWS (SEQ ID NO:8);
- (ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or
- (x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10),
- a peptide comprising amino acids having the sequence
- c) adjusting the pH of the solution of step b) until the peptide dissolves in the solution; and
- d) if necessary, adjusting the pH of the solution of step c) to a pH of 4-9, thereby manufacturing the pharmaceutical composition.
- In one embodiment, the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of at least 0.1 mg/ml.
- In another embodiment, the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of at least 0.5 mg/ml.
- In a further embodiment, the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of 2.5mg/ml, 2.0mg/ml, 1.0mg/ml, 0.5 mg/ml or 0.1 mg/ml.
- In another embodiment, the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is 5 mg/ml, 10 mg/ml or 15 mg/ml.
- In one embodiment of the process, the resulting final concentration of the substituted β-cyclodextrin in the pharmaceutical composition is from 70 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 80 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted α-cyclodextrin in the pharmaceutical composition of from 90 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 100 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a. final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 110 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 120 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 130 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 140 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 150 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition of from 160 mg/ml to 170 mg/ml.
- In one embodiment of the process, the predetermined concentration of the substituted β-cyclodextrin is such which results in a final concentration of substituted β-cyclodextrin in the pharmaceutical composition is 120 mg/ml.
- In a further embodiment, step b) further comprises mixing the solution for 1 hour.
- In a further embodiment, in step c) the pH is adjusted using HCl or NaOH 1.0N.
- In a further embodiment, the process further comprises filtering the solution of step d) through a cellulose acetate filter.
- In a further embodiment,
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of 2.5mg/ml, 2.0mg/ml, 1.0mg/ml, 0.5 mg/ml or 0.1 mg/ml;
- step b) further comprises mixing the solution for 1 hour; and
- in step c) the pH is adjusted using HCl or NaOH 1.0N, further comprising filtering the solution of step d) through a cellulose acetate filter.
- The subject invention also provides a composition prepared by any of the above processes.
- The subject invention also provides a lyophilized pharmaceutical composition comprising from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of
- a peptide comprising consecutive amino acids having the sequence
- (i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11) wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala;
- (ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;
- (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;
- (iv) GYNX19X29X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;
- (v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;
- (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;
- (viii) FSGYYWS (SEQ ID NO:8);
- (ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or
- (x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10),
- a solubility enhancer being a substituted β-cyclodextrin.
- In one embodiment of the lyophilized pharmaceutical composition, at least 0.5 mg/ml of the composition is the pharmaceutically acceptable salt of the peptide.
- The subject invention also provides a process of lyophilizing any of the above pharmaceutical compositions comprising the steps of:
- a) lowering the temperature of the pharmaceutical composition to -40°C;
- b) holding the temperature at -40°C for a predetermined time;
- c) raising the temperature of the solution to 20°C;
- d) holding the temperature at 20°C for a predetermined time; and
- e) reducing the pressure and holding the temperature at 20°C for a predetermined time, thereby lyophilizing the pharmaceutical composition.
- In one embodiment, step a) is performed within 2 hours.
- In another embodiment, step b) is performed within 3 hours.
- In another embodiment, step c) is performed over 13 hours.
- In another embodiment, step c) is performed at a pressure of 110µbar.
- In another embodiment, step d) is performed over 13 hours.
- In another embodiment, step d) is performed at a pressure of 110µbar.
- In another embodiment, in step e) the pressure is reduced to 10µbar.
- In another embodiment, step e) is performed over 5 hours.
- In another embodiment,
- step a) is performed within 2 hours;
- step b) is performed within 3 hours;
- step c) is performed over 13 hours and at a pressure of 110µbar;
- step d) is performed over 13 hours and at a pressure of 110µbar; and
- step e) is performed over 5 hours and the pressure is reduced to 10µbar.
- The subject invention also provides a lyophilized pharmaceutical composition prepared by any of the above processes.
- The subject invention also provides a process of lyophilizing any of the above pharmaceutical compositions comprising the steps of:
- a) lowering the temperature of the pharmaceutical composition to -45°C;
- b) holding the temperature at -45°C for a predetermined time;
- c) raising the temperature of the solution to -20°C;
- d) raising the temperature of the solution to 25°C; and
- e) holding the temperature at 25°C for a predetermined time, thereby lyophilizing the pharmaceutical composition.
- In one embodiment, step a) is performed within 6 hours.
- In another embodiment, step b) is performed within 3 hours.
- In another embodiment, step c) is performed over 19 hours.
- In another embodiment, step c) is performed at a pressure of 150µbar.
- In another embodiment, step d) is performed over 13 hours.
- In another embodiment, step d) is performed at a pressure of 150µbar.
- In another embodiment, step e) is performed over 8 hours.
- In another embodiment, step e) is performed at a pressure of 150µbar.
- In another embodiment,
- step a) is performed within 6 hours;
- step b) is performed within 3 hours;
- step c) is performed over 19 hours and at a pressure of 150µbar;
- step d) is performed over 13 hours and at a pressure of 150µbar; and
- step e) is performed over 8 hours and at a pressure of 150µbar.
- The subject invention also provides a lyophilized pharmaceutical composition prepared by any of the above processes.
- The subject invention also provides the above lyophilized pharmaceutical composition wherein the water content of the composition is less than 5%.
- In one embodiment, the water content of the composition is less than 4.0%.
- In another embodiment, the water content of the composition is less then 3.5%.
- The subject invention also provides a packaged pharmaceutical composition comprised of:
- a packaging material; and
- a predetermined amount of any of the above lyophilized pharmaceutical compositions.
- In another embodiment, the peptide has the formula
- NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:6).
- The synthetic peptides of this invention are based on the CDR of monoclonal pathogenic autoantibodies isolated from mice with experimental SLE. Such monoclonal antibodies are obtained from supernatants of hybridomas produced by fusion, for example, of spleen cells of C3H.SW mice immunized with an anti-16/6 Id mAb, with X63.653 plasmacytoma cells (Waisman and Mozes, 1993).
- Examples of such peptides are those of formulas Ia to Va herein, based on, respectively, the CDR1, CDR2 and CDR3 regions of the heavy chain of mAb 5G12 and the CDR1 and CDR3 regions of the heavy chain of mAb 2C4C2 (Waisman and Mozes, 1993), and analogs thereof.
- Peptides of the present invention are intended to include analogs of peptides Ia-Va including substitution, deletion and addition analogs as described herein. Substitution analogs have amino acid substitutions at different positions, these substitutions being made based on the volume, hydrophobic-hydrophilic pattern and charge of the amino acids.
- Amino acids may be divided along the lines of volume, hydrophobic-hydrophilic pattern and charge. With respect to volume, those of ordinary skill in the art understand that the amino acids with the largest volume are Trp, Tyr, Phe, Arg, Lys, Ile, Leu, Met and His, while those with the smallest volumes are Gly, Ala, Ser, Asp, Thr and Pro, with others being in between.
- With respect to hydrophobic-hydrophilic pattern, it is well known that the amino acids Gly, Ala, Phe, Val, Leu, Ile, Pro, Met and Trp are hydrophobic, whereas all of the remaining amino acids are hydrophilic. Among the hydrophilic amino acids, Ser, Thr, Gln, and Tyr have no charge, while Arg, Lys, His and Asn have a positive charge and Asp and Glu have negative charges.
- In selecting peptides to be tested for their potential in inhibiting the proliferative response of T lymphocytes of mice that are high responders to SLE-inducing autoantibodies, it is important that the substitutions be selected from those which cumulatively do not substantially change the volume, hydrophobic-hydrophilic pattern and charge of the corresponding portion of the unsubstituted parent peptide. Thus, a hydrophobic residue may be substituted with a hydrophilic residue, or vice-versa, as long as the total effect does not substantially change the volume, hydrophobic-hydrophilic pattern and charge of the corresponding unsubstituted parent peptide.
- It should be understood that other modifications of the peptides are also contemplated by the present invention. Thus, the peptide of the present invention is intended to include a "chemical derivative" thereof which retains at least a portion of the function of the peptide which permits its utility in preventing or inhibiting T cell proliferative responses and autoimmune disease.
- A "chemical derivative" of a peptide of the present invention contains additional chemical moieties not normally a part of the peptide. Covalent modifications of the peptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Many such chemical derivatives and methods for making them are well known in the art.
- Also included in the scope of the invention are salts of the peptides of the invention. As used herein, the term "salts" refers to both salts of carboxyl groups and to acid addition salts of amino groups of the peptide molecule. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases such as those formed for example, with amines, such astriethanolamine, arginine, or lysine, piperidine, procaine, and the like. Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid. Such chemical derivatives and salts are preferably used to modify the pharmaceutical properties of the peptide insofar as stability, solubility, etc., are concerned.
- The synthetic peptides and analogs thereof according to the invention may be selected from the group consisting of peptides having the sequences I to V herein, wherein:
- (i) the peptide of sequence I has the formula (SEQ ID NO:11):
T G Y Y X1 X2 X3 X4 X5 Q S P E K S L E W I G [I]
wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala.
In one embodiment, the peptide of sequence I has the formula (Ia)(SEQ ID NO: 1):
TGYYMQWVKQ S PE K S L E W I G (Ia)
- (ii) the peptide of sequence II has the formula (SEQ ID NO:12):
E I N P S T G G X6 X7 X8 X9 X10 A11 X12 K A K A T [II]
wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr.
In one embodiment, the peptide of sequence II has the formula (IIa) (SEQ ID NO:2):
EINPST GGT T YN Q KF KA K A T (IIa)
- (iii) the peptide of sequence III has the formula (SEQ ID NO:13):
Y Y C A R X13 XI4 X15 X16 P Y A X17 X18 Y W G Q G S [III]
wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser.
In one embodiment, the peptide of sequence III has the formula (IIIa) (SEQ ID NO:3):
Y Y CA R F L W E P Y A M D Y W G Q G S (IIIa)
- (iv) the peptide of sequence IV has the formula (SEQ ID N0:14):
G Y N X19 X20 X21 X22 X23 X24 S H G X25 X26 L E W I G [IV]
wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala.
In one embodiment, the peptide of sequence IV has the formula (IVa) (SEQ ID NO:4):
GYNMNWVKQ S H G K S LEW I G (IVa)
- (v) the peptide of sequence V has the formula (SEQ ID NO:15):
Y Y C A R X27 X28 X29 Y G X30 X31 X32 G Q T L [V]
wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala. - In one embodiment, the peptide of sequence V has the formula (Va) (SEQ ID NO:5):
YYCARSGRYG N Y W GQ T L (Va).
- Peptides Ia to IIIa are based on the CDR1, CDR2 and CDR3 regions, respectively, of the VH chain of mAb5G12, and peptides IVa and Va are based on the CDR1 and CDR3 regions, respectively, of the VH chain of mAb 2C4C2 (Waisman and Mozes, 1993).
- Once a peptide in accordance with the present invention is produced, its ability to inhibit the proliferative response of T lymphocytes of mice that are high responders to SLE inducing autoantibodies may be readily determined by those of ordinary skill in the art without undue experimentation using tests such as those described herein. One test which may be readily conducted is for the ability of substituted peptides to inhibit in vitro the proliferative responses of certain T cell lines and clones specific to SLE-inducing autoantibodies. The T cell lines and clones may, for example, be the T cell lines and clones specific to the 16/6 Id mAb (Fricke et al., 1991) established from immunized lymph node cells of mice by previously described methodology (Axelrod, O. and Mozes, E.
- Immunobiology 172: 99 (1986)). Cells are exposed to the stimulating antibody presented on irradiated syngeneic spleen cells in the presence of enriched medium every two weeks. The T cell lines are cloned by the standard limiting dilution technique. The proliferative responses of these T cell lines and clones are tested, for example, by the method described in Materials and Methods herein.
- Another test which can be conducted in order to select peptides having the desired activity is to test for the ability of the substituted peptides to inhibit the ability of the T cell lines and clones to provide help to peptide-specific B cells in the presence of the parent peptide. The substituted peptides may also be tested for their ability to bind directly, following biotinylation, to MMC Class II products on antigen-presenting cells of the relevant strains. For this purpose, N-terminal biotinylation of the relevant peptides is performed at 0ºC with an excess of biotin-N-hydroxysuccinimide in aqueous solution (Mozes, E. et al., EMBO J. 8: 4049 (1989)). Mouse splenic adherent cells or human peripheral blood lymphocyte (PBL)-adherent cells (1x106/sample) are incubated with biotinylated peptides in PBS containing 0.1% bovine serum albumin (PBS/BSA) at 37ºC for 20 hr, followed by incubation with phycoerythrin-streptavidin for 30 min at 4ºC. After each incubation, the cells are washed twice with the above solution. Thereafter, the cells are analyzed by flow cytometry using FACScan. In each analysis, a minimum of 5000 cells are examined (for above procedures, see, for example, Mozes et al., 1989; Zisman et al., 1991).
- A further test which can be conducted is to test for the ability of the peptides to inhibit cytokine secretion by the T cell line or by T lymphocytes of mice that are high responders to SLE-inducing autoantibodies. The cytokines are detected as follows: IL-1 activity is assessed either by ELISA using a pair of capture and detecting antibodies (as described below for IL-4, IL-6, IL-10) or using the LBRM-33(1A5) assay (Conlon, P.J. J. Immune. 134:1280 (1983))in which 1A5 cells are stimulated in the presence of phytohemagglutinin (PHA), with either supernatants or recombinant IL-1 at various concentrations to secrete IL-2. Following an overnight incubation, supernatants of 1A5 cells are transferred to the IL-2 dependent cytotoxic T lymphocyte (CTLL) line. Stimulation of the CTLL line by IL-2 is measured after 24 hr by incorporation of 3[H]-thymidine. IL-2 is directly detected using the IL-2 dependent CTLL line or by ELISA. Levels of IL-4, IL-6, IL-10, INFγ and TNFα in the supernatants are determined by ELISA using antibodies to the various cytokines (Phamingen, San Diego, Ca., USA) according to the manufacturer's instructions.
- Peptides which test positive in one or more of these in vitro tests will provide a reasonable expectation of in vivo activity. However, in vivo tests can also be conducted without undue experimentation. Thus, for example, adult mice may be injected with the candidate peptide at either day -3 or
day 0. The mice are then immunized with the disease-inducing autoantibody or with the peptide. Ten days later, lymph node cells of the mice are tested for their ability to proliferate to the immunogen in order to find out the inhibitory capacity of the candidate peptide. - Another such in vivo animal test consists in measuring the therapeutic activity directly in the murine model in vivo for the production of SLE as described above. The peptides can be injected into the mice in which experimental SLE is induced by different routes at different dosages and at different time schedules. In order to determine the pharmacokinetic parameters of the peptides, including volume of distribution, uptake into antigen-presenting cells and clearance, one can use biotinylated derivatives of the peptides. The concentration of the soluble fraction of the peptides in the various body fluids can be determined by ELISA, using avidin-coated plates and specific anti-peptide antibodies. Cell bound peptides can be analyzed by FACS, using fluorochromo-conjugated avidin or streptavidin. Furthermore, the treated mice can be tested periodically in order to determine the effect of the peptides on the autoantibody responses and on disease manifestations elicited in the mice by the SLE-inducing autoantibody.
- Another in vivo procedure consists in tolerizing newborn mice with the candidate peptide followed by immunization of the mice with the pathogenic autoantibody, such as 16/6 Id+, or with the same peptide, and following the disease manifestations, such as serological findings associated with leukopenia, elevated erythrocyte sedimentation rate, proteinuria, abundance of immune complexes in the kidneys and sclerosis of the glomeruli. It can thus be seen that, besides the preferred embodiments which have been shown to be operable in the examples herein, those of ordinary skill in the art will be able to determine additional peptides which will also be operable following the guidelines presented herein without undue experimentation.
- A relatively simple in vitro test can also be conducted in order to assay for the expected therapeutic efficacy of any given substituted peptide on any given SLE patient. In order to assess the ultimate goal of producing peptides that will bind with high affinity to the appropriate MHC Class II molecules but will not lead to further activation of T cells and will therefore have a therapeutic effect on SLE patients, the peptides may be assayed, following biotinylation, for their ability to bind directly to HLA Class II products on antigen-presenting cells in the peripheral blood lymphocytes of the SLE patients. Healthy control donors and control peptides may be used in such assays-to verify their specificity.
- In one embodiment, the therapeutic agent of the invention is a peptide selected from the group of peptides of formulas I to V herein, including peptides Ia to Va and substitution and/or deletion analogs thereof.
- In another embodiment, the therapeutic agent in accordance with the present invention is the form of a multi-epitope single peptide. Thus, in a preferred embodiment, dual petides consisting of two different peptides selected from the group of peptides of formulas I-V herein, are covalently linked to one another, such as by a short stretch of alanine residues or by a putative site for proteolysis by cathepsin. See, for example,
U.S. Patent 5,126,249 and European Patent495,049 - According to one embodiment of the present invention, one or more active peptides may be attached to a suitable macromolecular carrier or may be polymerized in the presence of glutaraldehyde.
- The peptides, polymers thereof or their conjugates with suitable macromolecular carriers, will be given to patients in a form that insures their bioavailability, making them suitable for treatment. If more than one peptide is found to have significant inhibitory activity, these peptides will be given to patients in a formulation containing a mixture of the peptides.
- The invention further includes pharmaceutical compositions comprising at least one synthetic peptide according to the invention, a conjugate thereof with a suitable macromolecular carrier or a polymer thereof optionally with a pharmaceutically acceptable carrier.
- Any suitable route of administration is encompassed by the invention, including oral, intravenous, subcutaneous, intraarticular, intramuscular, inhalation, intranasal, intrathecal, intraperitoneal, intradermal, transdermal or other known routes, including the enteral route.
- The dose ranges for the administration of the compositions of the present invention should be large enough to produce the desired effect, whereby, for example, an immune response to the SLE-inducing autoantibody, as measured by T cell proliferation in vitro, is substantially prevented or inhibited, and further, where the disease is significantly treated.
- The doses should not be so large as to cause adverse side effects, such as unwanted cross reactions, generalized immunosuppression, anaphylactic reactions and the like.
- Effective doses of the peptides of this invention for use in treating SLE are in the range of 1 µg/kg to 1 mg/kg body weight. The dosage administered will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- The synthetic peptides of the invention, particularly those of sequences I to V herein, are aimed at inhibiting or suppressing specific antigen responses of SLE patients, without affecting all other immune responses. This approach is of the utmost importance since most diagnosed patients are young women that have to be treated for many years and the currently accepted treatment for SLE involves administration of immunosuppressive agents, such as corticosteroids and/or cytotoxic drugs, that are both non-specific and have multiple adverse side effects.
- The preparations of the present invention may be given parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered by injection, inhalation, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
- The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- The phrases "systemic administration," "administered systematically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- Details of general formulation procedures and information on additional excipients may be found in Remington: The Science and Practice of Pharmacy, 20th Edition.
- Synthetic peptides can be produced as described in
PCT International Publication No. WO 02/067848 PCT International Publication No. WO 96/30057 - This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
- The synthesis of peptides I to V and the testing showing the effectiveness of the synthesized peptides for treating SLE in animal models is described in
PCT International Publication No. WO 96/30057 PCT International Publication No. WO 02/067848 - The peptides of the subject application are described in
PCT International Publication No. WO 02/067848, published September 6, 2002 -
Compound 1 is a synthetic polypeptide composed of 19 amino acids. It is provided as an acetate salt. The aqueous solubility of the peptide has been determined to be less than 0.5 mg/ml.Figure 1 showscompound 1 as an acetate salt. - In order to develop a formulation with peptide concentration exceeding 2 mg/ml, preferably up to 10 mg/ml, experiments with several solubility enahancers were performed. The preliminary experiments indicated that a concentration of 2 mg/ml cannot be easily attained. In order to develop a formulation for subcutaneous injection, it is also desirable that the pH be in the range of 4 to 9 and that the solution be iso-osmotic.
- Based on an extensive literature survey, a few principal approaches were adopted in order to produce a formulation with maximal solubility. The factors considered were:
- pH adjustment and buffers
- Solvents
- Co-solvents
- Solubilizing agents
-
Compound 1 was dissolved in the chosen solubility enhancer solution either separately or in combination with other excipients and the solutions were stirred for at least an hour. The pH was adjusted if needed. The solutions were visually examined to estimate the solubility and sent for analytical assay determination. For a few chosen formulations, biological activity was also tested. - Table 1 presents the type of solubility enhancers used for the formulation development. Tables 2 and 3 summarize the experiments that were performed with the various solubility enhancers. Table 2 summarizes the initial screening performed with peptide concentrations in the range of 5 to 10 mg/ml. The experimental work that was performed with higher peptide concentration was then repeated with the lower doses (see table 3).
- Initial tests indicated that
Compound 1 was more soluble at the limits of the desired pH levels, both acidic and basic, but was less stable at the basic pH range. Thus, several buffers and pH adjustment agents were tested, including acetate buffer, citrate buffer and sodium carbonate. None of the initially tested buffers achieved the desired peptide solubility level. - Only above pH 9.2 and below pH 3.0 were solubility levels of 2 mg/ml observed. Nevertheless, at the initial stage, formulations with acetate buffer and citrate buffer (with Mannitol as a tonicity agent) were selected for initial toxicology studies. These formulations were tested for biological activity and proven active
- Non aqueous solvents (see table 1) such as Ethanol, Glycerin, Propylene glycol, Chremophore and their combinations were tested but did not increase the solubility of
Compound 1. A solution of 30% DMA (dimethyl-acetamide) yielded solubility in the desired ranges (5 to 9 mg/ml), but was not suitable for a pharmaceutical formulation due to its toxicity profile. Improved solubility was also observed using 30% (w/w) PEG 400 (5 to 9 mg/ml). This latter formulation was chosen for the toxicology studies, but it has proved to be both inactive in the biological assay, and may have been the cause of some adverse effects in a mouse toxicity study. Thus, it was decided not to further pursue this formulation. In view of the preliminary experiments non-aqueous solvents were not used in the subject formulations. - Several amino acids (see table 1) including L-Arginine, L-Glutamic acid, L-Glycine and L-Lysine were tested to improve the protein solubility. The solubility of the peptide in L-Arginine was at the desired level but the resulting pH was above 9. An attempt to decrease the pH or use an Arginine HCl salt resulted in precipitation of the peptide. Human Serum Albumin was also tested and improved the solubility of the peptide at low peptide concentrations (1 mg/ml) (see table 3). However, due to its potential immunogenicity and the low peptide solubility, it was not utilized in further experiments.
- Bulking agents (see table 1) including Mannitol, Sorbitol and Dextran were tested alone and in combination with other excipients, but did not improve the solubility of the peptide in solution.
- Co-solvents (see table 1), including
Polysorbate 20 andPolysorbate 80 were tested alone and in combination with other excipients. While lower concentrations of Polysorbates (up to 6%) did not improve the solubility of the peptide, higher concentrations (up to 10% - see table 2) improved the solubility of the peptide up to 2 mg/ml. However, such high concentrations of Polysorbates were deemed unsuitable for pharmaceutical formulations. - Two types of cyclodextrins, both approved for use in marketed parenteral products, were also tested: Hydroxypropyl-β-cyclodextrin and Sulfobutylether-β-cyclodextrin (Captisol). Both markedly increased the solubility of the peptide (concentrations in the levels of 10 mg/ml for Hydroxypropyl-β-cyclodextrin and 2.5 for Captisol). The biological activity of the two cyclodextrin formulations was tested and was found to be equal to the activity of the peptide alone.
- CAPTISOL® is a commercially available polyanionic β-cyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl ether spacer group, or sulfobutylether (SBE). CAPTISOL® is the trade name for CyDex Inc.'s hepta-substituted sulfobutylether β-cyclodextrin (SBE7-β-CD) preparation (www.captisol.com). The structure of CAPTISOL® allows drug molecules to fit in the hydrophobic cavity, thereby isolating the drug molecule from the aqueous solvent. Because the outer surface of CAPTISOL® is hydrophilic, the solubility of the complexed drug molecule is thereby enhanced. The use of cyclodextrins to enhance the solubility of drug molecules is disclosed in
U.S. Patent Nos. 5,134,127 and5,376,645 . - According to the literature of CyDex Inc., CAPTISOL® is safe when administered parenterally and does not exhibit the nephrotoxicity associated with beta-cyclodextrin. Relative to beta-cyclodextrin, CAPTISOL® provides comparable or higher complexation characteristics and superior water solubility in excess of 90 grams/100ml - a 50-fold improvement.
- Several solubility enhancers were found to match the desired solubility range: DMA, PEG-400, dimethyl-acetamide, polyethylene glycol, polyoxylated castor oil, N-methyl-2-pyrrolidinone, 1-ethenyl-2-pyrrolidinone,
Polysorbate 20,Polysorbate 80, Hydroxypropyl-β-cyclodextrin and Sulfobutylether-β-cycldextrin (Captisol®). Of these solubility enhancers both cyclodextrins have proven to be superior with respect to solubility, biological activity and stability. Thus, it was decided to select Captisol® as the solubility enhancer for use in Example 5 formulations and to further study both cyclodextrin formulations. The final formulation for the Example 5 clinical studies consists of: 120 mg/ml of Captisol in water with the desired amount of peptide (0.5, 1.0 or 2.5 mg/ml), and HCl and NaOH for pH adjustment.Table 1: Solubility enhancers used for Compound 1 formulation developmentSolubility enhancer classification Solubility Enhancers Solvents Cremophor EL, CMC Ethanol, DMA, Gycerin, Propylene Glycol, PEG 400,Monotioglycerol Co-solvents Polysorbate 20, Ploysorbate 80Solubilizing.agents Argenine, HSA, Glycine, Creatinine, Glutamic acid, Lysine (acetate salt and free base), Captisol, Hydroxypropyl-β-cyclodextrin, Bulking agents Mannitol, Sorbitol, Dextrose, Lactose Dextran pH Adjustment Agents Citrate buffer, Acetate buffer, Sodium Carbonate Table 2. List of Cosolvents and Stabilizers evaluated in Compound 1 Peptide Formulations.Solubility Enhancer * % Used % of Standard amount from the literature Amount of peptide added (mg/ml) Assay, % pH of formulation Remarks Albumin (HSA), 1.5 0.4-5.0 5 6.0 Insoluble Dextrose 1.5 Adjust, to 4.1 Albumin (HSA), 1.0 0.4-5.0 5 - 5.8 Polysorbate 80, 0.6 0.8-4.0 Adjust. to 4.1 Insoluble Glycine 2.0 0.2-2.1 Arginine 1.5 0.8-1.6 15 93 9.8 Clear solution Arginine HCI 2.0 0.8-1.6 5 - 3.5 Insoluble Arginine 1.5 0.8-1.6 15 93 9.8 When the pH was lowered below 8.5 the peptide Lactose 1.5 precipitated and the solution turned into gel Captisol 10.0 Up to 30.0 10 86 4.9 Turbid solution 20.0 89 Adjust. to 4.4 CMC (carboxy methyl cellulose) in acetate 0.2 0.05M 5 90 5.0 For toxicology studies Creatanine 0.8 Up to 0.6 5 - 6.1 Adjust. to 4.1 Insoluble Cremophor EL 15.0 -10.0 5 - 4.0 Very turbid Ethanol 10.0 0.6-32.9 Dimethylacetamide 6.0 0.012-6.0 Dextran 4.0 to 15.0 3.0-30.0 5 - 3.9 Insoluble Dimethylacetamide (DMA) 6.0-20.0 0.012-6.0 5 - 4.6 Insoluble Solubility Enhancer * % Used % of Standard amount Amount of peptide added (mg/ml) Assay, % pH of formulation Remarks Dimethylacetamide (DMA) 25.0 0.012-6.0 5 87 5.1 Clear solution Dimethylacetamide (DMA) 30.0 0.012-6.0 10 93 5.1 Clear solution Ethanol 10.0 0.6-32.9 5 - - Insoluble Glutamic acid 2.0 precipitated 5 - 3.7 When the pH was increased above 4 the peptide precipitated and the solution turned into gel Glycerin 1.5 1.6-32.5 5 37 4.5 Insoluble Glycerin 30.0 1.6-32.5 5 - 3.7 Insoluble Glycerin, 10.0 1.6-32.5 5 12 6.5 Insoluble Polysorbate 80 0.6 0.8-4 Adjust. to 4.5 Glycine 0.4 0.2-2.1 5 - 4.6 Insoluble Hydroxypropyl β-cyclodextrins 20.0 Up to 30.0 10 99 4.6 Clear solution Lysine Acetate Salt 2.0 5 - 3.8 Insoluble Lysine Free base 2.0 5 - 9.2 When the pH was lowered below 8 the peptide precipitated and the solution turned into gel Mannitol in Citrate buffer 4.0 2.0-10.0 5 38 3.4 For toxicology studies 0.035M Mannitol 4.0 2.0-10.0 5 32 4.3 For toxicology studies in acetate buffer 0.05M Mannitol, 20.0 2.0-10.0 5 14 6.4 Insoluble Glycine 0.4 0.2-2.1 Adjust. to 4.5 Mannitol, 20.0 2.0-10.0 5 22 6.5 Insoluble Polysorbate 20 0.6 - Adjust. to 4.5 Monothioglycerol 1.0 0.1-10.0 5 - 4.5 Turbid solution PEG 400 30.0 Up to 30.0 5 88 4.2 Slightly opalescent Solubility Enhancer * % Used % of Standard amount from the literature Amount of peptide added (mg/ml) Assay,% pH of formulation Remarks PEG 400 30.0 Up to 30.0 10 89 4.2 Turbid solution PEG 400 30.0 Up to 30.0 5 94 4.2 Clear solution with DMA 6.0 0.012-0.6 PEG 400 10.0 6.0-18.0 5 58 4.2 Insoluble PEG 400 10.0 Up to 30.0 5 - 4.3 Insoluble DMA 10.0 0.012-0.6 PEG 400 10.0 Up to 30.0 5 - 4.1 Insoluble Propylene glycol PG 10.0 10.0 PEG 400 18.0 Up to 30.0 5 100 4.2 Clear solution Propylene glycol 50.0 10.0 Polysorbate 80 1.6 0.8-4.0 5 24 7.2 Insoluble Adjust. to 4.5 Polysorbate 80 6.0 0.8-4.0 5 - 3.9 Insoluble Polysorbate 80 6.0 0.8-4.0 5 - 4.0 Insoluble Creatanine 0.6 up to 0.6 Propylene glycol PG 10.0 10.0 5 - 4.2 Insoluble DMA 10.0 0.012-0.6 Propylene glycol PG 10.0, 30.0 10.0 5 - 4.2 Insoluble Sodium Carbonate 1.5 5 - 11.4 When the pH was lowered below 8.5 the peptide precipitated and the solution turned into gel Sorbitol 5.0 10.0-25.0 5 - 6.9 Turbid solution Adjust. to 4.5 Table 3: Compound 1 formulations at low Peptide concentrations Solubility Enhancer * % Used % of Standard amount from the literature Amount of peptide added (mg/ml) Assay,% pH of formulation Remarks Albumin (HSA), 5.0 0.4-5.0 1.0 90 6.9 Clear solution 2.5 - Adjust. to 4.5 Turbid solution Arginine 1.5 0.8-1.6 1.0 24 10.6 When the pH was lowered below 8.5 the peptide Adjust. to 8.5 precipitated and the solution turned into gel Captisol 12.0 Up to 30.0 1.0 106 5.3 Clear solution 2.5 100 6.5 to 8.5 Dextran 20.0 3.0-30.0 1.0 69 4.8 Turbid solution Adjust. to 4.0 Glycerin 30.0 1.6-32.5 1.0 - 4.8 Turbid solution Adjust. to 4.0 Mannitol 4.0 0.8-4.0 1.0 64 4.7 Turbid solution Adjust. to 4.0 Polysorbate 20 10.0 - 1.0 95 5.8 Clear solution 2.5 88 Adjust. to 4.8 Clear with small amount of precipitation Polysorbate 20 10.0 - 2.5 115 5.1 Clear solution Mannitol 2.0 2.0-10.0 Adjust. to 4.3 Polysorbate 80 4.0 0.8-4.0 1.0 91 5.5 Clear solution 6.0-10.0 2.5 89 Adjust. to 5.0 Slightly turbid solution Polysorbate 80 4.0 0.8-4.0 2.5 88 5.1 Slightly turbid solution Mannitol 2.0 2.0-10.0 Adjust. to 4.4 Propylene glycol PG 10.0 10.0 1.0 78 5.0 Turbid solution Adjust. to 4.4 Sorbitol 20.0 10.0-25 1.0 52 4.5 Turbid solution - Standard dissolution methods, such as mixing
dry Compound 1 and dry Captisol® into water or addingCompound 1 to a prepared solution of Captisol® and water did not result in complete dissolution at the desired concentrations. Several different concentrations of bothCompound 1 and Captisol® were tested at various pH levels. However, the following method for producing a solution ofCompound 1 in Captisol® resulted in complete dissolution at the desired concentrations. - Method:
- 1. Weigh the appropriate amount of Captisol® to give a final concentration of 120 mg/ml.
- 2. Add 80% of the final amount of water and mix for 10 minutes with a magnetic stirrer.
- 3.
Weigh Compound 1 to give a final concentration of 2.5 mg/ml, 2.0 mg/ml, 1.0 mg/ml, 0.5 mg/ml or 0.1 mg/ml. - 4. Add the peptide to the Captisol® solution. Mix for 1 hour.
- 5. Raise the pH to obtain clear solution (in the 2.0 mg/ml formulation there might be a need to raise the pH slightly above 9). pH should be adjusted using HCl 1.0 N and NaOH 1.0 N. Mix for 10 minutes.
- 6. Correct the pH to the range of 7.5 to 8.5 if needed (using either HCl or NaOH 1.0 N).
- 7. Add water to final volume.
- 8. Filter the solution through a 0.2µ cellulose acetate filter.
- 9. Record final pH.
- 10. Dispense into aliquots and store at the proper temperature.
- The current lyophilization process differs from other lyophilization processes in that the percentage of solids in the formulation is high (12%) whereas lyophilized products normally contain between 5 and 10% solids.
- The freeze drier used was an Edwards lyophilizer Lyoflex 0.6. The equipment IQ/OQ was performed and checked for compliance by quality assurance prior to the process development.
- Solutions of
Compound 1 and Captisol® at concentrations of 0.5 mg/ml, 1.0mg/ml and 2.5mg/ml ofCompound 1 were prepared. The fill-volume was adjusted 1 ml (1.05 gr). -
- 1. Freezing
- 2. Holding (at low temperature)
- 3. Drying under vacuum in two stages:
- 3.1. Primary drying - shelf warming to an upper hold temperature, controlling shelf temperature at the upper hold level.
- 3.2. Secondary drying - Pressure reduction to a minimal value at the upper hold shelf temperature.
- Freezing - Freezing was from room temperature to -40°C within 2 hours. Shelves were held at -40°C for 3 hours.
- Drying - Drying was performed at 110 µbar pressure. Shelf temperature was increased to 20°C over 13 hours and held at that temperature for additional 13 hours.
- Total process time was 31 hours.
- Water content results were:
- Batch no. 1: 3.8%
- Batch no. 2: 4.0% and
- Batch no. 3: 4.9%
- Since the water content results of the processes leading to
batches - Drying - Drying was performed at 110µbar pressure. Shelf temperature was increased to 20°C over 13 hours and held at that temperature for additional 13 hours (Batch 4) or 8 hours (Batch 5). Pressure was decreased to 10µbar for additional 5 hours.
- Total process time was 36 hours.
- Water content results were
- Batch 4: Placebo: 3.0%,
1 mg/ml: 3.9%. - Batch 5: Placebo: 4.1%
- As shown, a satisfactory lyophilization process for
Compound 1 with Captisol® was developed. Due to the high percentage of solids and hence the condensed cake, the developed process is longer then the currently available lyophilization cycles for peptides and it exhibits an additional secondary drying stage. Table 4 summarizes the developed process.Table 4 Step Compound 1 (Peptide) with Captisol® Loading 5° C Freezing 2 hours to -40°C Hold at low temp. 3 hours to -40°C Primary Drying: Warm to 20°C 13 hours pressure 110µbar Hold at 20°C 13 hours pressure 110µbar Secondary drying: Hold at 20° C 5 hours pressure 10µbar Storage at -20°C Process time 36 hours - The biological activity was monitored by inhibition of IL-2 secretion from
Compound 1 reference standard (RS) specific T-cells following subcutaneous (s.c.) treatment with the lyophilized compound solution, i.e. the drug product (DP), at two concentrations. The results of the treatment are compared to those of treating mice with Compound 1 (RS) in phosphate buffered saline (PBS). The results are shown in the tables below and inFigure 2 . -
- 1. Immunization Day 0 (
Compound 1 RS emulsified with CFA,
at all four footpads) - 2. Treatment
(s.c. at the back of the neck, in 200 µl solution)Day 0 - 3. In-vitro activation with:
Day 10- a.
Compound 1 RS at concentrations of 0; 0.5; 1; 2.5; 5; 10; 25; 50 and 100 µg/ml - b. a peptide with the reverse order of amino acids of Compound 1 (negative control).
- c. Con A (positive control).
- a.
- 4. Incubation of culture for 20 hrs at 37°C in a humidified 5% CO2 incubator.
- 5. IL-2 measurement by ELISA.
- The following abbreviations are used in the following description:
- CFA
- Complete Freund's adjuvant
- Con A
- Concanavalin A
- DP
- Drug Product
- DS
- Drug Substance
- EM-1
- Enriched DCCM-1 Medium
- EM-3
- Enriched RPMI-1640 + fetal calf serum medium
- FCS
- Fetal Calf Serum
- IFN-γ
- Interferon-gamma
- LN
- Lymph Node
- PBS
- Phosphate Buffered Saline
- RS
- Reference Standard
- s.c.
- Subcutaneous
- TB
- Trypan Blue
- TGF-β
- Transforming Growth Factor-beta
- WFI
- Water for Injection
- A group of 20 mice were immunized with 50 µg/mouse of
Compound 1 RS. The immunized mice were allocated to five treatment groups as follows: placebo, 25, 50, 100 and 200µg/mouse ofCompound 1 DP (subcutaneous administration). Ten days post immunization and treatment, LN was extracted and single cell suspension was prepared. The in-vitro secretion of IFN-γ and TGF-β by the cultured cells in response to activation with several concentrations ofCompound 1 RS was then measured. -
- 1. Immunization -
Day 0 - 2. Treatment with
Compound 1 DP -Day 0 - 3. In-vitro activation of LN cells from treated mice -
Day 10 - 4. Collection of culture media (for IFN-γ determination) -
Day 12 - 5. Collection of culture media (for TGF-β determination) -Day 13
- 6. ELISA for IFN-γ
- 7. ELISA for TGF-β
-
- Mice: 20 female BALB/c mice, supplied by Harlan animals breeding center, Rehovot.
- Age at immunization (week+days): 10
- Average weight of mice included in the experiment: 19.01 gr.
- 70% ethanol was prepared from 96% ethanol by diluting with purified H2O.
- CFA-
Compound 1 RS emulsion (500 µg/ml, 50 µg/mouse) was prepared as follows: - 1. 1.874 mg of
Compound 1 was dissolved in 1.87 ml of WFI to yield a solution of 1 mg/ml. - 2. The solution was tested with a pH indicator strip and found to have a pH of 5.
- 3. 1.5 ml of the solution were emulsified with 1.5 ml CFA resulting in a final concentration of 500 µg/ml.
- Treatment was by a s.c. injection of 200 µl solution.
-
- 1.2 gr of captisol® were dissolved in 10 ml of WFI to yield a solution of 12% captisol®.
- Mice were weighed before immunization. Average mice weight: 19.01 ± 0.97 gr
- The immunization was performed by injecting 100 microliters of the immunization emulsion (50 microliters into each hind footpad).
- Following the immunization step the mice were treated by s.c. injection of 200 µl from the designated
Compound 1 DP or 12% captisol® treatment solutions, at the back of their neck. - Mice were sacrificed by cervical dislocation. LN were extracted from the hind legs and were transferred to a sterile petri dish containing about 5 mL RPMI. The cells were extracted by gentle squeezing of the tissue against a 200 micrometer mesh stainless steel net. The cells were collected and centrifuged at 300 G for 10 minutes at RT.
- Single cell suspensions were prepared from pooled LN of each experimental group.
- 2.5 and 5.0 million cells/ml/well suspensions were cultured with
Compound 1 RS (0-100 µg/ml) in EM-1. - Secretion of IFN-γ and TGF-β, as indication of cellular response, were determined by ELISA of culture media (48hrs for IFN-γ and 72hrs for TGF-β).
Table 8: The in-vitro experimental groups Experimental Group Treatment In-vitro activation Article Cells/well Activation substance concentration A1-2.5 Control 12% Captisol®2.5 × 106 Compound 1RS 0; 3.125; 6.25; 12.5; 50 and 100 µg/ml Con A 2.5 µg/mlA1-5 5 × 106 A2-2.5 DP 25 µg/mouse2.5 × 106 A2-5 5 × 106 A3-2.5 DP 50 µg/mouse2.5 × 106 A3-5 5 × 106 A4-2.5 DP 100 µg/mouse2.5 × 106 A4-5 5 × 106 A5-2.5 DP 2.5 × 106 A5-5 200 µg/ mouse 5 × 106 -
Table 9: Results of cell counting and preparation of cell suspensions (10 x 106/ml) Grp Vol. (ml) Dilutn. factor Viable cells Dead cells %Viable cells %Dead cells Average viable cells Total viable cells (× 106) EM-1 to add (ml) for suspension of 10 × 106 cells/ ml A1 10 16 115 -- 100 -- 112 179.2 17.9 109 -- 100 -- A2 10 16 50 4 92.6 7.4 47.5 76 7.6 45 2 95.7 4.3 A3 10 16 80 4 95.2 4.8 80.5 128.8 12.8 81 5 94.2 5.8 A4 10 16 87 -- 100 -- 89 142 14.2 91 -- 100 -- A5 10 16 120 2 98.4 1.6 112.5 180 18 105 2 98.1 1.9 - The 10 x 106 cells/ml suspensions were diluted 1:2 by adding 5 ml EM-1 to 5 ml cells suspension.
- 3 tissue culture plates were prepared. The following was added to each plate.
-
- 0.5 ml of cells suspension
- 0.5 ml of culture media (EM-1)
-
- 0.5 ml of cells suspension
- 0.5 ml of
Con A 5 µg/ml in EM-1 (final conc. 2.5 µg/well) -
- 0.5 ml of cells suspension
- 0.5 ml of
Compound 1 RS 6.25 - 200 µg/ml (final conc. 3.125 - 100 µg/ml/well) - After the 48-wells plates were prepared, 96-wells plates were prepared by applying 100 µl from the cell suspension and 100 µl from the activation solutions.
- The culture plates were incubated at 37°. C in a humidified 5% CO2 incubator, for either 48 or 72 hrs.
- The cultured plates were centrifuged at 300 g for 10 minutes at RT. Supernatants (850 µl from each well) were transferred either to mirror plates or to tubes. The supernatant was then divided into working aliquots (two aliquots of 200 and one aliquot of 450 µl), in order to avoid repeated freeze/thawing of the samples. Each tube was labeled with the following details:
- 1. Experimental code and time post incubation.
- 2. Group and sample number
- 3. Activator and concentration.
- 4. Date of sup collection
- The supernatants were stored at -20°C until used for ELISA.
-
Table 10: Summary of Groups Experimental Groups: Immunization Treatment In-vitro Exp.Groups Immunization dose Sub group Article activation A1 12% Captisol® Placebo control A2 Compound 1 25µg/M A 50µg/ mouse A3 Compound 1 50µg/ M Compound 1 RS 3.125-100µg/ ml A4 Compound 1 100µg/ M A5 Compound 1 200µg/M Table 11-A: Final cytokine concentrations Final cytokine (pg/ml)(2.5 million cells/well) Compound 1 concentrationPlacebo 50µg/M 100µg/M 200µg/M 3.125µg/ml 321.3 54.1 64.5 103.9 6.25µg/ml 238.6 81.8 116.1 126.1 12.5µg/ml 397.1 123.1 180.9 129.0 25µ/ml 655.5 215.1 262.8 240.3 50µg/ml 573.9 292.5 518.3 378.1 100µg/ml 926.0 531.8 582.7 524.1 Con A 322.6 356.2 337.4 BQL Table 11-B: Final cytokine concentrations Final cytokine (pg/ml) (5 million cells/well) Compound 1 concentrationPlacebo 25µg/M 50µg/M 100µg/M 200µg/M 3.125µg/ml 522.3 BQL 76.2 90.8 204.4 6.25µg/ml 634.8 BQL 109.2 157.8 244.1 12.5µg/ml 962.8 41.9 179.5 257.1 466.1 25µ/ml 967.4 70.0 277.9 421.7 660.5 50µg/ml 1338.8 104.2 373.4 739.7 922.5 100µg/ml 2010.2 185.2 547.0 995.5 1006.2 Con A 6839.8 2995.3 4837.0 10126.8 7722.8 - The results are also presented in
Figures 3-4 . -
- 1. In the placebo group, a linear dose response upon
Compound 1 activation in-vitro was shown. This graph resembles the graph obtained for the Ex-vivo model with the same immunization dose (50µg/mouse) and culturing medium (EM-1). - 2. There was a dose response upon
Compound 1 activation in vitro within all the tested groups. - 3. Significant inhibition of IFN-γ secretion was seen with all the doses used for treatment (an average of 95% inhibition with treated dose of 25µg/mouse). A reverse correlation between the dose served for treatment and % inhibition can be found, mainly when 5x106 cells/well were used. When 2.5x106 cells/well were used, treatment of animals with 50µg/mouse gave better inhibition than 100 or 200µg. The point of 25µg is missing (lack of cells).
- 4. A better inhibition was seen when 5x106 cells/well were used instead of 2.5x106 cells/well.
- 5. In the linear range of the graphs, SD of % inhibition was low.
- 6. A technical problem with Con A is apparent when 2.5x106 cells/well were used.
-
- 1. In the placebo group, no dose response upon in vitro activation with
compound 1 was seen. TGF-β secreted level was below the detection limit of the ELISA in all other treatment groups. - The purpose of this study was to optimize the freeze drying cycle for
Compound 1 with captisol® for injection to improve the shape of the lyophilization cake and avoid collapse and cracking. Thus it was decided to improve and optimize the lyophilization cycle. This cycle is transferred to the production lyophilizers for the manufacturing of the phase I batches. - Batches of peptide at concentrations of 0.5 mg/ml 1.0mg/ml, 2.5mg/ml and Placebo were prepared and several freeze drying cycles were performed. The freeze drier used was an Edwards lyophilizer Lyoflex 0.6.
- Solubility, water content and cake appearance were tested. According to the obtained results a new lyophilization cycle for
Compound 1 was selected. Due to the high percentage of solids (12%) and hence the condensed cake, the new process is longer than the lyophilization cycle in Example 3 and exhibits an additional primary drying stage. Table 12 summarizes the differences between the processes.Table 12 Step Lyoph. cycle for Compound 1 and Captisol® of Example 3New Lyoph. cycle for Compound 1 andCaptisol® Loading 5° C 5° C Freezing 2 hours to -40°C 6 hours to -45°C Hold at low temp. 3 hours to -40° C 3 hours to -45°C Primary Drying: to 20°C to -20°C Stage I 13 hours pressure 110µbar 19 hours pressure 150µbar Stage II - to 25°C 13 hours pressure 150µbar Hold at 20°C (25°C) 13 hours pressure 110µbar 8 hours pressure 150µbar Secondary drying: Hold at 20° C 5 hours pressure 10µbar - Storage at 5° C 5°C Process time 36 hours 49 hours - Patients participating in clinical trials are to be treated with
Compound 1 using Captisol® (sulfobutyl ether beta-cyclodextrin sodium) as the excipient. For this reason, it was important to determine whether treatment of (NZBxNZW)F1 mice with the formulation ofCompound 1 given in Captisol® would have the same beneficial effects on lupus symptoms as observed when this strain of mice was treated withCompound 1 in PBS. - To this end, (NZBxNZW)F1 female mice (about 8 months old) were divided into 3 groups that were treated subcutaneously once a week for 10 weeks either with Captisol® alone (n=8) or with 25 or 50 µg/
mouse Compound 1 in Captisol® (n=9 and 10, respectively). These doses were selected since prior studies indicated tHat doses in this range were more effective in ameliorating SLE symptoms than the higher doses tested (100 and 200 µg/mouse). The same batch of drug substance was used in this study and in the first Phase I clinical trial withCompound 1. - The mice were followed for anti-dsDNA antibodies and for proteinuria. When the mice were sacrificed, the intensity of ICD was determined in kidneys.
- As can be seen in
Figure 5 , no significant differences between groups could be observed in the levels of dsDNA-specific antibodies after 10 treatment injections. - Table 13 also shows that the beneficial effect of treatment with
Compound 1 could be observed starting from the 5th injection and it was sustained up to the 10th injection. The mean levels of proteinuria in the Captisol® control group were consistently higher than in the Compound 1 -treated groups. Table 13 also shows that a reduction in the intensity of ICD was observed in kidneys of bothCompound 1 dose groups. There was an overall trend showing that the lower dose (25 µg/mouse) was more effective than the higher dose (50 µg/mouse) in reducing the clinical symptoms of SLE in these mice.Table 13. Clinical Symptoms of SLE in (NZBxNZW)F1 Mice Treated with 25 or 50 µg/mouse Compound 1 (in Captisol®) Study Group Mean Proteinuria ± SEM (g/L) ICDa (Mean ± SEM) Number of Weeks Following Treatment Initiation 5 7 8 10 Captisol® 1.81 ± 1.22 (n=8) 5.74 ± 3.13 (n=8) 4.5 ± 2.92 (n=7)b 4.46 ± 2.93 (n=7)b 2.29 ± 0.28 (n=7) Compound 1 (50 µg/mouse) 0.75 ± 0.3 (n=10) 0.81 ± 0.3 (n=10) 1.09 ± 0.4 (n=10) 1.29 ± 0.3 (n=10) 1.90 ± 0.23 (n=10) Compound 1 (25 µg/mouse) 0.16 ± 0.05 (n=9) 1.26 ± 1.09 (n=9) 0.5 ± 0.31 (n=9) 0.56 ± 0.3 (n=9) 1.22c ± 0.32 (n=9) a ICD=Immune Complex Deposits. ICD intensity scale: 0=none; 1=moderate; 2=severe; 3=severe/extremely intense.
b The death of one animal with a high level of proteinuria resulted in a lower group mean.
c p<0.05 (compared to Captisol®-treated control mice; Mann-Whitney). -
Figure 6 shows representative sections of one kidney from each treatment group. The top row sections are from a Captisol®-treated mouse, the mid-row sections are from a mouse treated with 50 µg/mouse Compound 1 and the bottom row sections are from a mouse treated with 25 µg/mouse Compound 1. It can be seen that the intensity of immune complex deposits observed in kidney sections of mice treated with Compound 1 (dissolved in Captisol®) at either dose level was much lower than that observed in the control group. - This was the first clinical study with
Compound 1 in captisol® in humans, conducted in France. Its main objective was to evaluate tolerability and safety ofCompound 1 in captisol®, administered as a single sc injection to SLE subjects. Its secondary objective was to evaluate immunological responses following a single sc dose ofCompound 1 in captisol® in these subjects. - Thirty-six (36) subjects participated in the study. To be eligible for inclusion in the study, SLE patients must have fulfilled at least four criteria used for the diagnosis of lupus by the American College of Rheumatology. Patients must also have had stable, mild/moderate disease and score less than or equal to 10 on the SLE Disease Activity Index, SLEDAI.
- Each patient received a single sc injection of reconstituted
Compound 1 for injection or its matching placebo (Captisol®) according to the following group assignment: - ▪ Group A: Placebo (Captisol®)
- ▪ Group B: 0.5
mg Compound 1 in Captisol® - ▪ Group C: 1
mg Compound 1 in Captisol® - ▪ Group D: 2.5
mg Compound 1 in Captisol® - A standard battery of safety tests, including blood and urine collection for laboratory tests, was performed at screening, during the day of dosing at 24 hours post-dose and at 2, 4 and 8 weeks following dosing. Prior to dosing, and on scheduled follow-up visits, blood samples were withdrawn for SLE-related immunological tests, anti-Compound 1 antibodies and PBL proliferation assay. The following immunology tests were performed:
- ▪ Coomb's (direct and indirect)
- ▪ C3, C4 and CH50
- ▪ Total IgG, IgM and IgA
- ▪ ANA, anti-dsDNA (Farr assay), anti-ssDNA
- ▪ Anti-ENA (including anti-La, anti-Ro, anti-RNP, anti-Sm)
- ▪ Anti-cardiolipin antibodies
- ▪ VDRL
- ▪ FTA antibodies
- ▪ Rheumatoid factor
- The safety and tolerability of
Compound 1 in captisol® in the subject population was evaluated on the basis of the following criteria: - ▪ Occurrence of AEs, including SLE flare
- ▪ Vital signs
- ▪ 12-lead ECG
- ▪ Changes in physical examination
- ▪ Routine clinical laboratory tests
- ▪ SLEDAI score
- ▪ Immunological test results
- Study Principal Investigators and Respective Study Sites: Six (6) study centers in France:Prof. Jean Charles Piette (Hopital La Pitie Salpetriere, Paris), Prof Oliver Meyer (Hopital Bichat, Paris), Prof. Jean Revuz (Hopital Henri Mondor, Creteil), Prof. Loic Guillevin (Hopital Avicenne, Bobigny), Prof. Eric Hachulla (Hopital Claude Huriez, Lille Cedex), Prof.- Xavier Mariette (Hopital Bicetre, Kremlin Bicetre).
- Vials of
Compound 1 in Captisol® (120mg/vial) were injected subcutaneously as a single dose per subject in the following dosages: - 0.5
mg Compound 1/vial in Captisol®,1mg Compound 1/vial in Captisol® and 2.5mg Compound 1/vial in Captisol®. - Placebo for Compound 1: 120 mg Captisol®/vial (identical in appearance to vials of
Compound 1 in Captisol®). - This was a multi-center, randomized; double blind, placebo-controlled, four-arm study, using a single subcutaneous injection of
Compound 1 or placebo. SLE patients were screened up to 21 days prior to baseline procedures. Each eligible subject was randomized to one of the 4 treatment groups: subcutaneous injection of either 0.5, 1 or 2.5mg Compound 1 or its matching placebo. All subjects were admitted to the clinic on pre-dosing day. Each subject received a single dose of one of the above listed treatments. Subjects were discharged from the clinic 24 hours after dosing. Subjects were further monitored atweeks Weeks Weeks Weeks - Thirty six (36) subjects were randomized into this study as follows; 9 subjects into the 0.5 mg treatment group, 9 subjects into 1 mg treatment group, 10 subjects into the 2.5 mg treatment group, and 8 subjects into the placebo treatment group.
- Eligible subjects for this study were SLE patients who fulfilled at least four diagnostic criteria of the American College of Rheumatology (ACR). Their disease condition had to be stable, mild to moderate with a score equal to or less than 10 on the SLE disease activity index,
year 2000 updated (SLEDAI 2K). - Excluded from participation were SLE patients who reported unstable or severe asthma, stroke, acute myocardial infarction, unstable angina, cerebral hemorrhage and pulmonary embolism during the six months prior to study screening. SLE patients wno had any clinically significant or unstable medical or surgical conditions, diabetes mellitus, liver disease (cirrhosis, active hepatitis, portal hypertension, and/or ascites), clinically significant hypertension, a medical history of any malignancy, dialysis, or chronic obstructive pulmonary disease (COPD) were also excluded from study participation.
- Also excluded from study participation were SLE patients who underwent plasmapheresis or were treated during the three months prior to screening with one of the drugs listed below: prednisone 30mg/day or greater (or an equivalent dose of another corticosteroid), intravenous corticosteroids, intravenous immunoglobulin G (IgG), oral anticoagulants and any cytotoxic agents (e.g. azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, methothrexate, tacrolimus.
- In addition, SLE patients initiating treatment with corticosteroids (more than ± 10 mg/day prednisone, or an equivalent dose of another corticosteroid) and/or anti-malarials, during the last 3 months prior to screening were excluded from the study.
- While an effort was made to retain baseline SLE medical treatments throughout the course of the study, investigators could nevertheless change participant medical treatment at any time during the study to maintain and optimize patient welfare.
- The following safety parameters were assessed at Screening, during the hospitalization and at follow-up visits including Termination visit: vital signs (systolic blood pressure, diastolic blood pressure, pulse, oxygen saturation, temperature and weight), 12-lead ECG, change in physical examination and clinical routine laboratory safety tests. Adverse events were recorded at the Dosing Day and at each visit thereafter.
- SLE-related immunological tests were performed at Screening, during the hospitalization and at follow-up visits including Termination visit.
- Drug-related immunological responses were followed by using the PBL proliferation assay and anti-Compound 1 antibodies assay at the Dosing Day and at follow-up visits including Termination visit.
- Disease activity assessment using the SLE disease activity index score,
year 2000 updated (SLEDAI 2K) was assessed at Screening, during the hospitalization and at follow-up visits including Termination visit. - SAS® version 9.0 software was used to analyze and present data collected during this study. No power calculation was performed and no formal hypothesis testing was conducted for this Phase Ia study.
- The incidence and the frequency of adverse experiences was presented by System Organ Class and preferred terminology according to MedDRA dictionary version 5.0. The data is tabulated by treatment group.
- Descriptive statistics of laboratory values including number of observations, mean, standard deviation, minimum and maximum were determined for Screening, Day 1 (pre dose),
Day 2,Week - Descriptive statistics for vital signs including number of observations, mean, standard deviation, median, minimum and maximum values were determined for Screening, Day 1 (pre and post dose, and at each time point)
Day 2,Weeks - Descriptive Statistics of Weight (kg) at baseline, termination and change from baseline is presented by treatment group.
- Descriptive statistics of ECG parameters at baseline, termination and changes from baseline are presented. Shift analysis is presented as tables of shift from baseline to termination between normal/abnormal or present/absent ECG parameters. Potentially clinically significant (PCS) QTc (Bazett) measurements were identified according to the predefined criteria. Tables of shift analysis between PCS and non-PCS Absolute QTc (Bazett) and incidence table of PCS change in QTc (Bazett) from baseline to any visit are presented.
- Physical examination results are analyzed by incidence of subjects with abnormal or normal findings for each body system at Baseline and Termination visit. Shitt analysis between normal to abnormal and vice versa was also applied. When no change from baseline occurred, it was defined as "other".
- For immunological parameters, descriptive statistics, including number of observations, mean, standard deviation, median, minimum and maximum values were calculated and are presented by treatment group and visit. Change from baseline to each follow-up visit is also presented by treatment group. Where applicable, number and percent of subjects with negative/positive results is presented by treatment group and visit.
- Descriptive statistics, including mean, standard deviation, median, minimum and maximum values of SLEDAI 2K are presented.
- Thirty six (36) study subjects entered and completed this study per protocol. The majority of subjects (34) in all treatment groups were female (94.4%) and Caucasian (30, 83.3%). The mean age for all treatment groups was 35.6 years (range of means from 32 to 39 years). Most of the subjects (91.7%) had between 4 to 6 American College of Rheumatology (ACR) diagnostic criteria and a mean group SLEDAI 2K score ranged from 2.1 to 4.1.
- There was no prominent difference between study drug treatment groups and the placebo group in the incidence of AEs. The most common AEs in all groups were headache, classified as mild or moderate in nature and injection site reaction classified as mild in nature. Dose response was not seen. No serious adverse event (SAE) or AE classified as severe occurred during the study.
- No clinically significant effect attributable to study drug was seen for hematology, biochemistry or urinalysis values.
- No clinically significant effect attributable to the study drug was seen for vital signs parameters (systolic blood pressure, diastolic blood pressure, pulse, oxygen saturation).
- No clinically significant effect attributable to the study drug was seen for temperature and weight.
- No differences of clinical significance were seen between Compound 1 -treated groups and placebo for categorical ECG measurements and digitized ECG parameters. No PCS QTc absolute value and no QTc change from baseline > 60 msec was recorded. A similar number of subjects in Compound 1 -treated and placebo groups had QTcB change from baseline between 30 and 60 msec.
- No clinically significant effects of
Compound 1 on physical exam were noted. - Evaluation of serum samples from all subjects indicated that a single subcutaneous administration of
Compound 1 at the dose levels of 0.5, 1 and 2.5 mg/patient did not induce the development of anti-Compound 1 specific antibodies. Seven subjects had a response toCompound 1 above the cut-off. These elevated levels of antibodies were already present prior to dosing. No increase in the levels of antibodies was observed in the follow up period (two months) of the study. The sera of these subjects were analyzed for the isotype of the reactive antibodies. The response in two of the subjects was associated with the IgM isotype and with the IgG isotype in two others. None of the seven had specific IgE antibodies. - The peripheral blood lymphocytes (PBL) assay showed that 50 % of the subjects (18) were classified as responders (SI>2) with similar distribution in all treatment groups. The T cell response was relatively low and no association between
Compound 1 treatment dose or concentration used in the assay and responder non-responder status could be detected, taking into consideration that only a single SC dose of the study drug was administered. Also, no indication of increased incidence of responder status over time was observed. The tetanus toxoid (TTX) assay that serves as a safety control shows that the response to TTX was preserved throughout the study period in all treatment groups indicating thatCompound 1 in captisol® did not change the immunological response to TTX recall antigen. - The immunological findings are the result of the administration of only a single dose of the
study drug Compound 1. - No clinically significant effects of
Compound 1 on the SLEDAI score (change of ≥ 3, ≤ 12 points) were noted during the study except for one subject in the 0.5 mg treatment group for whom a change in the SLEDAI score of 2 to 10 points was recorded between baseline andweek 4 on the basis of an urinalysis showing pyuria. This urinalysis finding was not confirmed by the investigator as a lupus flare per protocol definition and was resolved with no treatment change. - This Phase Ia study showed that a single subcutaneous injected dose of
Compound 1 of 0.5, 1 or 2.5 mg in 120 mg Captisol ® was safe and well tolerated and allows continuation to a phase Ib multiple dose study. - This study is being performed in order to evaluate the safety and tolerability of repeated
Compound 1 sc administration to SLE subjects. The study's secondary objective is to evaluate immunological responses following repeated sc administration ofCompound 1 in Captisol® in SLE subjects. -
Compound 1 is given in doses of 0.5, 1.0 or 2.5 mg in Captisol®. The investigational product is administered every other day (excluding weekends) for a total of 12 sc injections, i.e. 3 doses a week for 4 weeks. Subjects are monitored on planned visits scheduled at 2, 4, 8 and 12 weeks after start of dosing. Safety and tolerability are evaluated using tests similar to those described in the Phase Ia Clinical Study above. - This Phase Ib study shows that multiple subcutaneous injected doses of
Compound 1 of 0.5, 1 or 2.5 mg in 120 mg Captisol ® are safe and well tolerated. - Human SLE patients (32 patients) were bled and their sera were tested by ELISA for their ability to bind the peptides Ia, IIa and IIIa, a control peptide p195-212 (a myasthogenic peptide described in
PCT publication No. WO 94/00148 - Detection of the antibodies was conducted on plates that were coated with 10µg/ml of peptides Ia, IIa, IIIa, p195-212 or mAb 5G12, in PBS for 2 hr, washed and blocked with 1% ovalbumin in PBS for an additional 2 hr. ELISA was continued as described after blockage in Example 2 of
PCT International Publication No. 96/30057 - As shown in
Fig. 7 , SLE patients exhibited significantly higher levels of antibodies that bind either peptide Ia (open squares), IIa (open diamonds), IIIa (open circles), or mAb 5G12 (open triangles), in comparison to healthy controls (peptide Ia-healthy = closed diamonds; peptide IIa-healthy = crossed circles; peptide IIIa-healthy = inverted open triangles; 5G12-healthy = half filled squares). No binding could be observed when either sera of patients or controls were tested on plates coated with the non-relevant peptide p195-212 (p195-212-SLE = crossed squares; p195-212-healthy = half filled diamonds). The results indicate a correlation between the whole antibody molecule and the CDR-based peptides on the level of antibody titers. - Peripheral blood lymphocytes (PBL) were isolated from the blood of SLE patients or healthy controls using ficol gradient. Thereafter, the PBL were incubated in the presence of different concentrations of the peptides Ia, IIa or IIIa, or the human 16/6 Id mAb for 24 hr, when a sample was taken for IL-2 measurement. The assay was continued for a total of 7 days, and 3H-thymidine was added for the last 16 hr. Proliferation was detected by reading the amount of radioactivity incorporated into the DNA of the cells.
- As is seen in Table 14, a lower proportion of the PBL taken from SLE patients reacted to the peptides or to the 16/6 Id mAb, when compared to the healthy controls. The results are expressed in percentage of responder (34% in the first line) and the actual number of patients (11 out of 32: 11/32).
- Similar results were obtained when the levels of the IL-2 produced by the PBL in the presence of the peptides or the 16/6 Id mAb were tested, as shown in the next example.
Table 14. Proliferation of PBL from SLE Patients and Healthy Controls in Presence of mAb 16/6 Id and Peptides Ia-IIIa EMI29.1SLE Patients Healthy Controls 16/6 Id 34% 11/32 72% 5 pep Ia 21% 7/32 44% 11/25 pep IIa 9% 3/32 28% 7/25 pep IIIa 31% 10/32 60% 15/25 - PBL were isolated from blood of SLE patients or healthy controls using ficol gradient, and were incubated as in Example 11. A sample of 50µl was removed 24 hr after the assay was started, and incubated in the presence of IL-2 sensitive cells (CTLD) for 24 hr, after which 3H-thymidine was added for 16 hr, and the plates were harvested and counted on a beta counter.
- As in Table 14, it can also be seen from Table 15 that a lower proportion of the PBL taken from SLE patients reacted to the peptides or to the 16/6 Id mAb, when compared to the healthy controls, thus indicating that the response to the peptide corresponds to that of T cells of the patient to the pathogenic human autoantibody.
Table 15: Production by PBL of SLE Patients and Healthy Controls in Presence of mAb 16/6 Id and Peptides Ia-IIIaSLE Patients Healthy Controls 16/6 Id 31% 10/32 66% 17/25 pep Ia 16% 5/32 56% 14/25 pep IIa 90/ o 3/32 32% 8/25 pep IIIa 16% 5/32 64% 16/25 - The human hCDR1 (SEQ ID NO: 6) and hCDR3 (SEQ ID NO: 7) are shown below.
- GYYWSWIRQPPGKGEEWIG (hCDR1)
- YYCARGLLRGGWNDVDYYGMDV (hCDR3)
- The peptides were prepared by methods well-known in the art, for example, by chemical solid phase or solution phase synthesis using an automated synthesizer by using the manufacturer's protocols for t-butyloxycarbonyl (t-Boc), fluorenylmethoxycarbonyl (Fmoc) or other alpha-amino acid protecting group procedure essentially as described (see, for example, Peptides: Synthesis, Structure and Applications, ed. By B. Gutte, Academic Press, 1995; Peptide Synthesis Protocols, ed. by M. Pennington and B. Dunn, Humana Press,1994 ; Schnolzer M. et al., In situ neutralization in Bocchemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40: 180-193,1992).
- Sixty-two patients, 9 males (14.5%) and 53 females (85.5%) with SLE participated in the study. The mean age at diagnosis was 32.95 ±12.92 (range 12-61) years and the mean follow-up period was 10.98 ± 10.76 (range 1-32) years. All patients fulfilled at least 4 of the American College of Rheumatology (ACR) revised diagnostic criteria for SLE (Tan E.M. et al., Arthritis Rheum 25: 1271-77 (1982)). Patients were recruited from three Israeli Medical Centers (Kaplan, Rehovot; Ichilov, Tel Aviv; Asaf-Harofeh, Rishon Lezion). Disease activity was determined according to the SLEDAI lupus activity index (Bombardier C. et al., Arthritis Rheum 35: 630-40 (1992)). A control group of 36 sex- and age-matched healthy control volunteers was studied concomitantly with the SLE patients. The study was approved by the Ethical Committee of the Medical Center.
- It was of interest to investigate whether the peptides hCDR1 and hCDR3, which are based on the CDR1 and CDR3 of the human 16/6Id mAb, are capable of inhibiting the specific proliferative responses of PBL of SLE patients to the human 16/6Id mAb. To this end, we first had to identify the patients whose PBL could be stimulated to proliferate by the human 16/6Id mAb (responders).
- Therefore, PBL of 62 consecutive SLE patients were cultured in the presence of the human 16/6 Id and their proliferative responses and ability to secrete IL-2 were determined. PBL of 24 out of the total of 62 (39%) and of 23 out of 55 (42%) SLE patients tested responded (SI ≥ 2, range 2-5.6) by proliferation and by IL-2 secretion (SI ≥ 2, range 2-60), respectively. The frequency of responders in the group of SLE patients was lower than that observed in the group of healthy donors that was tested as control. Thus, PBL of 21 out of a total of 36 (58%) healthy donors responded by proliferation to the 16/6 Id. The extent of proliferation (SI levels) was similar for the SLE patients and for the healthy controls who responded to the 16/6 Id. However, as shown in
Figure 8 , the optimal response to the 16/6 Id of PBL of the control donors was observed at higher concentrations of 16/6 Id as compared to the SLE patients. - No differences could be demonstrated between gender and age of SLE patients that responded to the 16/6 Id and of the non-responder group of patients. However, the patients whose PBL proliferated in response to the 16/6 Id were sick for a shorter period of time (a mean of 9.78±8.36 vs. 11.73±12.06 years for responders and non-responders, respectively; P ≤ 0. 036). Table 16 summarizes the clinical characterization of the 16/6 Id responder and non-responder groups of SLE patients. As can be seen in the Table, both groups were similar in most SLE related clinical manifestations. The SLE disease activity score (SLEDAI) and the number of SLE diagnostic criteria were also similar in the two groups. Nevertheless, a higher frequency of neurological (both seizures and psychosis) and hematological involvement and a lower rate of renal involvement were noted in the responder group of patients in comparison to the group of non-responders. However, probably because of low number of patients in the relevant subgroups, the above differences did not reach statistical significance. Moreover, relatively less responder patients were determined between those treated with either steroids or cytotoxic agents at the time of the study. It is noteworthy that significantly more patients who never received steroids responded to the 16/6 Id in comparison to the non-responder group (54% vs 21% ; P=0.023).
- It is noteworthy that the efficacy of the CDR-based peptides to inhibit the proliferative responses of PBL of healthy donors to the 16/6 Id was much lower than that observed for PBL of SLE patients (not shown).
Table 16. Clinical and laboratory characterization of SLE patients. A: Diagnostic Criteria* All Patients Responders Non-responders Number of Patients (%) 62(100) 24(39) 38(61) Malar rash 19/62 (30.1) 8/24 (33.3) 11/38(29) Discoid rash 9/62 (15) 3/24 (12.5) 6/38 (16) Photosensitivity 21/62 (34) 9/24 (37.5) 12/38 (32) Mucosal ulcers 17/62 (27.4) 8/24 (33.3) 9/38 (23.7) Arthritis 46/62 (74.2) 19/24 (79.2) 27/38 (71) Serositis 14/62 (22.6) 5/24 (20.8) 9/38 (23.7) Neurologic 5/62(8.1) 4/24 (16.7) 1/38 (2.7) disorders ‡ Renal disorder ‡ 24/62 (38.8) 7/24 (29.2) 17/38 (44.8) Hematological disorders ‡ 44/62 (71) 19/24 (79.2) 25/38 (65.8) ANA 61/62 (98.4) 24/24 (100) 37/38 (92.1) A-dsDNA 54/62 (87.1) 19/24 (79.2) 35/38 (92.1) APLA 35/62 (56.5) 12/24 (50.0) 23/38 (60.53) B: Disease Activity SLEDAI Score 6.65±5.12 7.29±1.06 6.24±0.84 Number of ACR 5.44±1.39 5.54±0.33 5.34±0.2 diagnostic criteria C: Current Treatment NSAIDS 17/62 (27.4) 6/24 (25) 11/38 (29) Anti-Malarial 37/62 (59.7) 15/24 (62.5) 22/38 (57.9) Steroids‡ 33/62 (53.2) 11/24 (45.8) 22/38 (57.9) Cytotoxic‡ 10/62 (16.1) 2/24 (8.3) 8/38(21) *Clinical involvement was defined according to the ACR revised criteria. Antinuclear antibodies (ANA) and anti-dsDNA antibodies were determined by Hep2 cells and Crithidia luciliae, respectively. Anti-phospholipid antibodies (APLA) were defined as activity in one or more of the following assays: false positive VDRL, lupus anti-coagulant (LAC) or ELISA for anticardiolipin antibodies.
† The anti-malarial agent, hydroxychloroquine, was used at a dose of 200-400 mg/day ; Steroid treatment was defined as a daily dose: 5mg of prednisone ; cytotoxic agents used were cyclophosphamide (0.75-1.0g/m2 ; monthly) or azathioprine (100-150 mg/day).
‡ Parameters for which tendency was observed towards differences between the two groups of responder and non-responder SLE patients. - To test the ability of the peptides hCDR1 and hCDR3 to inhibit the proliferative response of PBL of SLE patients to the human 16/6Id mAb, PBL (2x105/well) of SLE patients were stimulated in vitro in triplicates with different concentrations (0.1-20µg/well ) of the human 16/6Id mAb in the absence or presence of the peptides hCDR1 and hCDR3 (either 50 or 100 µg/well). Following 6 days of incubation, 3H-thymidine (0.5 µCi of 5 Ci/mmol) was added to each well for additional 18 hours of incubation. Cells were then harvested and radioactivity was counted using a β-counter. Results were expressed as mean counts per minute (cpm) of triplicate cultures. Stimulation indices (the ratio of mean cpm at the optimal concentration of 16/6Id to mean cpm without 16/6Id) were then calculated. A stimulation index (SI)≥2 was considered positive.
- PBL of 24 out of the total of 62 (39%) SLE patients were found to proliferate to the 16/6Id mAb. The ability of the peptides hCDR1 and hCDR3 to inhibit the proliferative responses to the whole molecule of the 16/6Id autoantibody was tested on PBL of 19 responders SLE patients.
- Table 17 shows the results of these experiments. Inhibition of above 50% of the proliferative capacity was considered positive. The Table represents the highest positive inhibition capacity for each peptide. It can be seen that the human hCDR1 and hCDR3 inhibited the proliferation of PBL of 16/19 (84.2%) and 15/19 (78.9%), respectively, of the 19 responders tested. Both peptides inhibited the proliferation of PBL of 18/19(95%) of responders tested. It can also be seen in the Table that the magnitudes of inhibitions were similar for both peptides. Thus, it can be concluded that peptides based on CDR1 and CDR3 of the human 16/6Id mAb are efficient inhibitors of the proliferation of PBL of SLE patients to the human 16/6Id mAb.
Table 17 Inhibition of proliferation of PBL of SLE patients by peptides hCDR1 and hCDR3. Number Percent Inhibition hCDR1 hCDR3 1. 62 <50 2. 70 75 3. 69 <50 4. <50 <50 5. 88.5 87.5 6. 80 80 7. 76 70.4 8. 58 56 9. 69.5 65 10. 68.2 71.8 11. <50 72 12. 82 86 13. 63 64 14. 56 74 15. 63 69 16. <50 68 17. 70.5 77.8 18. 51.5 <50 19. 63 60.8 Mean±SD 68.12±9.57 71.82±8.44 - It is important to demonstrate that the inhibitory effects of the hCDR-based peptides are specific to SLE-associated responses. To this end the peptides hCDR1 or hCDR3 were added to cultures of PBL of SLE patients that were stimulated with the mitogen phytohemagglutinin (PHA,2 µg/ml). The results of such an experiment performed with PBL of one SLE patient is shown in
Figure 9 . The peptides hCDR1 and hCDR3 could not inhibit the proliferative responses (expressed in cpm) of the PBL to the mitogen PHA and the proliferative responses were similarly high in the absence (black column) or presence of either hCDR1 or hCDR3. - In another experiment, cultures of PBL of SLE patients were stimulated with the human 16/6Id mAb and then incubated with the human peptides hCDR1 or hCDR3 or with the peptide IIIa as a control. The results of such an experiment performed with PBL of one SLE patient are shown in
Figure 10 . As shown inFigure 10 , whereas both peptides hCDR1 and hCDR3 based on the human autoantibody inhibited efficiently the proliferative responses of PBL to the human 16/6Id mAb, the peptide mCDR3 based on the CDR3 of the murine antibody (i.e. peptide IIIa) did not inhibit the proliferation. - Two additional control peptides were used in these experiments, namely peptides synthesized at the reversed order of the Ia and IIIa peptides, and the results are shown in
Figure 11 . It can be seen that the two reversed peptides failed to inhibit significantly the proliferative responses of the PBL of the SLE patient to human 16/6Id mAb while peptides hCDR1 and hCDR3 did inhibit efficiently the proliferation, demonstrating that the inhibition of proliferation by the human hCDR-based peptides is specific to the peptides and to the SLE-associated T cell responses. - It was of interest to find out whether the hCDR peptides are capable of inhibiting IL-2 secretion by PBL of SLE patients following stimulation with the human 16/6Id mAb. Such inhibition might also suggest that the human CDR-based peptides inhibit the proliferative responses to the 16/6Id mAb at least partially by down-regulating IL-2 secretion. To this end, PBL of SLE patients were incubated with the human 16/61d mAb in the absence or presence of the peptides hCDR1 or hCDR1 Supernatants of the cultures were collected following 48 hours of incubation. Assays to determine levels of IL-2 in the supernatants were performed using the CTLL IL-2 dependent line. Briefly, cells of the CTLL line (2x104/well) were incubated in the presence of the different supernatants for 24 hours, followed by the addition of 3H-thymidine for an additional 18-hour incubation period. Cells were then harvested and radioactivity counted using a β-counter. Results were calculated based on recombinant human IL-2 used as a standard. The ability of the peptides to inhibit the IL-2 secretion of PBL of 23 responders stimulated by the human 16/6 Id was tested. The results, summarized in Table 18, show that hCDR1 and hCDR3 inhibited the secretion of IL-2 by PBL of 21/23 and 19/23 patients, respectively. Inhibition of proliferative responses of PBL directly correlated with IL-2 inhibition by the CDR-based peptides. Thus, inhibition of IL-2 secretion was observed in all cases where inhibition of proliferation were determined.
- The results obtained with PBL of one SLE patient represented in
Figure 12 (secretion of IL-2 is expressed in pg/ml) show that both hCDR1 and hCDR3 inhibited 100% of the IL-2 secretion by PBL of a SLE patient triggered by the human 16/6Id mAb.Table 18. Inhibition of IL-2 secretion by hCDR1 and hCDR3 Peptide Inhibitory Maximum Activity* inhibition % % hCDR1 91 (21/23) 84±31 hCDR3 83 (19/23) 78±34 *IL-2 secretion in the presence of 16/6 Id alone was considered as 100%. Inhibition of 50% or more was considered significant. - In attempts to shed light on the mechanisms by which the human CDR-based peptides inhibit the proliferative responses to the human monoclonal anti-DNA 16/6Id antibody, the levels of the immunosuppressive cytokine TGF-β in the supernatants of the cell cultures were determined. The rationale behind these experiments is based on our previous findings of elevated levels of TGF-β in cultures of splenocytes of mice with SLE either induced with the human anti-DNA 16/6Id mAb or spontaneous {(NZB x NZW) F1 mice} following treatment with the peptides based on mouse CDR (Eilat, E. et al., Proc. Natl. Acad. Sci. U. S. A., 98, 1148 (2001)). The elevation in the levels of TGF-β correlated with amelioration of disease manifestations in the treated mice.
- For this purpose, supernatants were removed from cultures of PBL of various SLE patients following 48 hours incubation with the human 16/6Id mAb in the absence or presence of the peptides hCDR1 or hCDR3. TGF-β was determined by ELISA according to the manufacturer's instructions. Briefly, Maxisorb plates (Nunc) were coated with recombinant human TGFβsRII/Fc chimera (R & D Systems) diluted in PBS (100 ng/ml). After blocking, cell supernatants were added. After 18 hours incubation the detecting biotinylated anti-human TGF-β antibody (R & D Systems) was added. The substrate solution used was the TMB Colour Reagent (Helix Diagnostics) and enzyme activity was evaluated by the MRX ELISA reader using the 570 nm and 630 nm filters. The results are summarized in Table 19.
- The results in
Figure 13 demonstrate that peptides hCDR1 and hCDR3 triggered a significant up-regulation in the secretion ofTGF-ss (expressed in pg/ml) by the PBL of one representative SLE patient that were stimulated with the pathogenic human 16/6Id mAb.Table 19 Up-regulation of TGF-β secretion of 16/6 Id-induced stimulation of PBL of SLE patients with hCDR1 and hCDR3 peptides. Peptide Up-Regulation of TGF-β % Maximum Up-regulation % hCDR1 100(19/19) 305±221 hCDR3 100 (19/19) 338±242 - Secretion of TGF-β in the presence of 16/6 Id alone (mean63625 pg/ml) was considered as 100%. Results are expressed as percent secretion above that in the presence of16/6Id alone.
- In the present example, we determined the levels of MMP-9 and MMP-2 in sera of 40 patients with SLE and we demonstrate that MMP-9 but not MMP-2 activity is significantly elevated in sera of SLE patients compared to healthy controls. High MMP-9 activity correlated with the presence of discoid rash, Raynaud phenomenon, pneumonitis, mucosal ulcers and the presence of anti phospholipid antibodies (APLA). In addition, elevated levels of MMP-9 correlated with SLE' activity in the group of male patients.
- Patients. Forty patients, 32 females and 8 males with SLE participated in this study. All patients revealed at least four of the revised diagnostic criteria of the American College of Rheumatism (ACR) for the diagnosis of SLE (Winchester RJ. Systemic lupus erythematosus pathogenesis. In: Koopman WJ, ed. Birmingham. Alabama: William and Wilkins,pp. 1361-91 (1996)). Twenty-five sex-and age-matched healthy volunteers served as a control group in our studies. The mean age of patients at diagnosis was 29±9.7 (range 15-48) years and the mean follow-up period was 11±10 (range 1-32) years. Disease activity was determined according to the SLEDAI lupus activity index (Bombardier et al., 1992) and by the BILAG index (Hay E.M. et al., Q. J. Med. 86: 447-58 (1993)). The study was approved by the ethic committee of the Kaplan Medical Center, Rehovot, Israel.
- Measurement of MMP-2 and MMP-9 by activit assay kits. Activities of MMP-2 and MMP-9 were measured by specific Biotrak MMP-2 or MMP-9 activity assay kits (Amersham Pharmacia Biotech UK Limited, UK) according to the manufacturer's instructions. Sera were diluted 1:100 and 1:32 for the determination of MMP-2 and MMP-9 activities, respectively. The appropriate standards were added in each assay. In order to measure the total content of the MMPs, activation of the pro form of the MMPs was performed using p-aminophenylmercuric acetate (APMA).
- Measurement of MMP-2 and MMP-9 activities by gel zymography. MMP-2 and MMP-9 activities were tested by gelatin zymography. A 5µl sample of serum was separated by an 8% SDS-PAGE gel polymerized with 1 mg/ml gelatin. Gels were washed once for 30 min in 2.5% Triton X-100 to remove the SDS, and once for 30 min in the reaction buffer containing 50 mM Tris-HCI, 200 mM NaCl, 10 mM CaCl2 and 0.02%(w/v) Brij 35 (pH 7.5). The reaction buffer was changed to a fresh one, and the gels were incubated at37°C for 24 h. Gelatinolytic activity was visualized by staining the gels with 0.5% Coomassie brilliant blue and was quantified by densitometry.
- Statistical analyses. The data were evaluated using chi-square or Fisher exact tests, unpaired t-test and two tailed P-values. Pearson, Spearman and multivariate analyses were also used.
- As described above and in
PCT International Publication No. WO 02/067848 Figure 14 . As can be seen in this figure, levels of MMP-9 are elevated in the sera of SLE patients when compared to healthy controls. Densitometric analysis of the zymograms of sera of 40 SLE patients and 25 healthy controls indicated that the mean MMP-9 activity for SLE patients was 109±5.6 densitometry units and for the healthy controls, 76.5±4.2 densitometry units (P=0.0001). Activity values of above 85 densitometry units (mean of healthy controls + 2 s.e.) were considered high. The results demonstrated high activity levels of MMP-9 in 68% of the SLE patients. Only 3% of healthy controls exhibited high MMP-9 activity (P=0.001). Densitometric analysis of MMP-2 levels in the same serum samples revealed that the differences in MMP-2 activity between sera of SLE patients and of healthy controls were not significant. Thus values of 109±7 and of 123±5. (mean activity densitometry units ± s.e.) were determined for healthy controls and SLE patients, respectively (P=0.0531). To quantify the activity levels of MMP-9 and MMP-2 in the serum further, we used activity assay kits. -
Figure 15 shows that the activity of MMP-9 is elevated by threefold in sera of SLE patients compared with sera of healthy controls, and this elevation is statistically significant (P=0.0302). In contrast, the differences in the levels of MMP-2 between the two groups are not significant (P=0.1254). - Since we, as well as others (Ebihara I. et al., Am J Kidney Dis 32: 544-50 (1998); Ebihara I. et al., Nephron 83: 169 (1999) detected high MMP-9 levels in sera of patients with non-SLE chronic renal failure (e. g. diabetes mellitus, hypertension) probably due to the retention of the enzyme, we analysed the correlation between levels of MMP-9 and kidney function in the group of SLE patients tested. No correlation was observed between creatinine levels and MMP-9 levels (r2=0.01), indicating that the elevated levels of MMP-9 in SLE patients were not the result of retention of the enzyme due to renal impairment.
- The elevation in the activity levels of MMP-9 in sera of SLE patients prompted us to look for possible correlation between clinical and laboratory parameters, and serum MMP-9 levels. Statistical analysis (chi-square or Fisher exact tests) was performed by investigating the number of patients with high and normal MMP-9 levels for each clinical manifestation (Table 20) as well as by taking into consideration the actual mean activity levels of MMP-9 for patients with or without a certain clinical symptom. The results were similar by both analyses. It is noteworthy that for all clinical symptoms, the percent of patients with elevated MMP-9 levels is much higher than that in the group of healthy controls. Levels of MMP-9 did not correlate with gender, duration of disease or the age of its onset (Pearson, Spearman).
- Table 20 shows the clinical and laboratory characteristics of the SLE patients according to their MMP-9 activity levels (lower or equal to healthy controls=normal). High levels of MMP-9 correlated significantly with the presence of Raynaud phenomenon (P=0.0138) and APLA (P=0.041). A strong correlation could be observed with pneumonitis, discoid rash, neurological disorders and mucosal ulcers. However, the number of patients with the latter manifestations was too small to perform a statistical analysis. Multivariate analysis revealed that Raynaud phenomenon and low complement (C3, C4) levels are positively correlated with high MMP-9 levels (P=0.0001 and 0.0137, respectively). In contrast, photosensitivity, arthritis and hematological disorders are negatively correlated with MMP-9 activity levels (P=0.0381, 0.0014 and 0.0065, respectively).
Table 20 Clinical characteristics of SLE patients with high and normal MMP-9 activities according to their MMP-9 levels. MMP-9 LEVELS (%) High Normal Number of Patients (%) 40(100) 27 (68) 13 (32) Photosensistivity 13 8 (62) 5(38) Mucosal ulcers 9 8(89) 1 (11) Malar rash 9 7(78) 2(22) Discoid rash 5 5(100) 0(0) Raynaud phenomenon 8 8(100) 0(0) Vasculitis 18 14 (78) 4 (22) Arthritis 31 21 (68) 10 (32) Serositis 9 7(78) 2(22) Pneumonitis 4 4(100) 0(0) Neurological disorders 4 4 (100) 0(0) Renal disorder 16 11(69) 5(31) Hematological Disorders 29 18 (62) 11 (38) ANA 40 27 (68) 13 (32) αds-DNA 36 24 (67) 12 (33) APLA 25 20 (80) 5 (20) Low complement (C3,C4) 30 21 (70) 9(30) - Clinical involvement was defined according to the ACR revised criteria (Winchester, 1996). Anti-nuclear antibodies (ANA) and anti-ds DNA antibodies were determined by using Hep2 cells and Crithidia lucilie, respectively. Antiphospholipid antibodies (APLA) were defined as reactivity with one or more of the following assays: false positive VDR, lupus anti-coagulant (LAC) or ELISA for anticardiolipin antibodies.
- We also looked for a possible correlation between SLEDAI and MMP-9 activity in male (
Figure 16A ) and female patients (Figure 16B ). Interestingly, the correlation coefficient was significant and positive for men (r2 = 0.6333) but insignificant and negative for women (r2 = 0.0571). Similar results were obtained using the BILAG scoring system. Thus, a positive correlation coefficient between MMP-9 activity and BILAG scores was observed for men (r2 = 0.6442) and an insignificant one for women. - It was also of interest to determine whether a correlation exists between the use of various treatment modalities by the patients and MMP-9 activity. As can be seen in Table 21(A), there was no significant correlation between the current treatment of the patients and MMP-9 activity. However, when we looked at treatment of patients at any time during their disease course (Table 21(B)), high MMP-9 levels were associated with usage of cytotoxic agents (82%).
Table 21 Treatment modalities of SLE patients according to their MMP-9 levels. Total Number of Patients MMP-9 Levels (%) High Normal A. Current treatment. Cytotoxic agents 8 6 (75) 2 (25) Steroids 23 17 (74) 6 (26) Anti-Malarial 21 14 (67) 7 (33) NSAID 7 5 (71) 2 (29) B. Treatment along the follow up period. Cytotoxic agents 17 14 (82) 3 (18) Steroids 29 19 (66) 10 (34) Anti-Malarial 26 16 (62) 10 (38) NSAID 18 12 (67) 6 (33) - The anti-malarial agent hydroxychloroquine was used at dose of 200-400 mg/day. Steroid treatment was defined as a daily dose ≥ mg of prednisone. Cytotoxic agents used were cyclophosphamide (0.5-1g/m2 monthly) or azathioprine (100-150 mg/day).
- Since disease activity varies over time, we measured the activity levels of MMP-9 and MMP-2 in the serum of individual patients that were sampled during 4-6 years of follow-up. Sera of nine patients taken at different time points were analysed. Levels of MMP-2 did not vary significantly between patients and healthy controls. In 5 out of the 9 patients tested, variations in MMP-9 activity in serum samples of individual patients could be observed with time. The results for 2 representative SLE patients are shown in
Figures 17A-B . As can be seen, MMP-9 activity, but not MMP-2 activity, has been changing with time in the same patients. These changes were not associated with disease activity indices as determined by either the SLEDAI or BILAG systems. Changes in MMP-9 activity were not detected in sera of 5 healthy controls that were sampled at different time points (data not shown). In 4 other SLE patients, no substantial changes in MMP-9 or MMP-2 activity were observed with time, and MMP-9 activity levels remained either high or low, depending on the individual patient. - The present study demonstrates for the first time the involvement of MMP-9 in human SLE. We show that the activity of MMP-9, but not MMP-2, is significantly elevated in sera of 68% of SLE patients compared with healthy controls. High MMP-9 levels correlated with Raynaud phenomenon, pneumonitis, neurological disorders, discoid rash and the presence of APLA. Changes in MMP-9 activity were observed in serum of the same patient at different periods of the disease. MMP-9 activity levels did not correlate with disease activity index (SLEDAI, BILAG) in female patients, but correlated with SLE activity in the group of male patients.
- The present study shows that activity levels of MMP-2 are not elevated significantly in sera of SLE patients. These results are compatible with those reported previously (Zucker, S. J Rheumatol. 26,78 (1999)) that MMP-2 levels were not increased in SLE. Levels of MMP-2 were also constitutive and unchanged in other pathological conditions (like optic neuritis and multiple sclerosis) in which levels of MMP-9 were elevated relatively to the healthy controls (Gijbels K et al., J. Neuroimmunol. 41: 29-34 (1992).; Paemen, L. et al., Eur. J. Neurol. 1: 55-63 (1994)).
- Involvement of an additional MMP, namely, MMP-3 was suggested in the pathogenesis of SLE, since it was significantly increased in sera of patients with SLE (Kotajima, L. et al., Clin. Exp. Rheum. 16: 409-415 (1998)). The frequency of SLE patients with elevated MMP-9 activity (68%) shown in the present example, resembles the frequencies reported (Kotajima et al., 1998) for high MMP-3 levels in SLE (76%) and in RA (82%) patients. Furthermore, the MMP-3 transcript was shown to increase significantly with the progression of nephritis in (NZB x NZW) F1 mice (Nakamura, T. et al., Clin. Sci. 85:295-301 (1993)).
- The origin of the elevated MMPs in sera of SLE patients is not known. MMP-9 has been shown to be secreted by peripheral blood cells such as T cells, neutrophils, and macrophages (for review, see Goetzl, E. J. et al., J. Immunol. 156: 1-4 (1996)). The fact that no correlation was found between MMP-9 activity levels and the number of peripheral blood cells in the patients may suggest that MMP-9 was not secreted by peripheral blood immune cells but rather, by SLE-affected organs like kidneys or lungs/pleura. The observation that all SLE patients with pneumonitis exhibited high MMP-9 activity levels may suggest the diseased lung as a source of high MMP-9 levels. Moreover, the association between cytotoxic treatment, which represents the severity of SLE-related organ impairment, and high levels of MMP-9 in the sera may also support the notion that the diseased organs are the source of MMP-9 activity in SLE patients. Nevertheless, the possibility still exists that less peripheral blood lymphocytes secreted higher activity levels of MMP-9.
- TNF-α and IL-1 were shown to play an important role in the pathogenesis of SLE both in the human disease (Dean G.S. et al., Ann Rheum Dis 59: 243-51 (2000)) and in murine models (Segal R. et al., J Immunol 158: 3009-16 (1997); Theofilopoulos A.N. et al., Ann Rheum Dis 58 (suppl): 149-55 (1999); Eilat et al., 2001). It has been shown in several systems that these cytokines induce MMP-9 production (Guedez, L. et al., Crit. Rev. Oncogenesis 7: 205-225 (1996)), and thus, it is possible that the induction of the latter MMPs is part of the pathogenic effect of these cytokines in SLE. It has been reported that levels of MMP-9, that are secreted spontaneously by peripheral blood monocytes of healthy individuals, were upregulated upon exposureto TNF-α and IL-1β (Saren P. et al., J Immunol 157: 4159-65 (1996)). In addition, MMPs of both T cells and macrophages facilitate secretion of TNF-α by cleavage of the membrane-bound form (Gearing A.J.H. et al., Nature 370:555-7 (1994)). Thus, these examples demonstrate the mutual regulatory effects of MMP on the proinflammatory cytokines and vice versa. Nevertheless, the fact that in the sera of some of the patients the activity levels of MMP-9 remained within the normal range during the follow-up period, whereas high activity levels of MMP-9 were measured in the sera of most patients, may suggest the involvement of genetic factors in the regulation of the latter.
- The results herein indicate that MMP-9 might play a role in the pathogenesis of SLE, and that measurement of plasma/serum activity levels of this metalloproteinase may provide important information when monitoring patients treated with drugs that interfere with MMP-9 activity.
-
- <110> Cohen-Vered, et al., sharon
- <120> PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS
ERYTHEMATOSUS - <130>
2609/68811-A - <140>
10/758,397
<141> 2004-01-14 - <160> 18
- <170> PatentIn version 3.1
- <210> 1
<211> 20
<212> PRT
<213> Artificial Sequence - <220>
<223> synthetic peptide based on CDR of mouse autoantibody - <400> 1
- <210> 2
<211> 20
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 2
- <210> 3
<211> 20
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 3
- <210> 4
<211> 19
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 4
- <210> 5
<211> 17
<212> PRT
<213> Artificial sequence - <220>
<223> synthetic peptide based on CDR of mouse autoantibody - <400> 5
- <210> 6
<211> 19
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 6
- <210> 7
<211> 22
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 7
- <210> 8
<211> 7
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 8
- <210> 9
<211> 16
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 9
- <210> 10
<211> 18
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <400> 10
- <210> 11
<211> 20
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> x= Met, Ala or Val - <220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X= Gln, Asp, Glu or Arg - <220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X= Trp or Ala - <220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X= Val or Ser - <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X= Lys, Glu or Ala - <400> 11
- <210> 12
<211> 20
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> x= Thr, Val or Ala - <220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X= Thr, val or Ala - <220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> X= Tyr or Phe - <220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> X= Asn or Asp - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> X =Gln or Glu - <220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> X= Lys or Glu - <220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> X= Phe or Tyr - <400> 12
- <210> 13
<211> 20
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X= Phe, Thr or Gly - <220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X= Leu, Ala or Ser - <220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X= Trp or Ala - <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X= Glu or Lys - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> X= Met or Ala - <220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> X= Asp, Lys or Ser - <400> 13
- <210> 14
<211> 19
<212> PRT
<213> Artificial sequence - <220>
<223> synthetic peptide based on CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X= Met or Ala - <220>
<221> MISC_FEATURE
<222> (S)..(S)
<223> X= Asn, Asp or Arg - <220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X= Trp or Ala - <220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X= Val or Ser - <220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X= Lys or Glu - <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X= Gln or Ala - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> X= Lys or Glu - <220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> X= Ser or Ala - <400> 14
- <210> 15
<211> 17
<212> PRT
<213> Artificial sequence - <220>
<223> Synthetic peptide based on CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X= Ser or Phe - <220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X= Gly or Ala - <220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X= Arg, Ala or Glu - <220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> X= Asn or Asp - <220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> X= Tyr or Phe - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> x= Trp, His or Ala - <400> 15
- <210> 16
<211> 19
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide basedon CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X= Gly or Thr Gly - <220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X= Arg or Lys - <220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X= Pro or Ser - <220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> X= Gly or Glu - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> X= Lys or Asp - <220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> X= Glu, Leu or Ser - <400> 16
- <210> 17
<211> 22
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide basedon CDR of mouse autoantibody - <220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X= Gly or Phe - <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X= Arg or Ala - <220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X= Gly or Ala - <220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> X= Gly or Ala - <220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> X= Trp or Ala - <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> X= Asn or Ala - <220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> X= Tyr or Trp - <220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> X= Met or Gln - <400> 17
- <210> 18
<211> 19
<212> PRT
<213> Artificial Sequence - <220>
<223> Synthetic peptide of 19 amino acids based on the complementarity-determining region 1 (CDR1) of human anti-dsDNA mAb denoted 16/6 Id - <400> 18
Group | Immunization with |
|
A | ||
50 |
50µg Compd. 1 RS in PBS | |
B | 200µg Compd. 1 RS in PBS | |
C | 50µg DP(batch 2) | |
D | 200µg DP (batch 2) | |
F | Placebo (12 % captisol) |
Treated with: | ||||||||||
Group | F | A | B | C | D | |||||
Activator | Concentration of activator (pg/ml) | 12% captisol® Ampulized | Compd. 1 |
% inhib. | Compd. 1 |
% inhib. | |
% inhib. | |
% inhib. |
Con A | 2.5 | 5,825 | 6,215 | 5,403 | 3,537 | 4,069 | ||||
Compd. 1 |
0 | BQL | BQL | BQL | BQL | BQL | ||||
Compd. 1 RS | 0.5 | 11 | 9 | 10 | 8 | BQL | ||||
Compd. 1 |
1 | 10 | BQL | BQL | BQL | BQL | ||||
Compd. 1 RS | 2.5 | 15 | 8 | 51 | BQL | NA | 6 | 61 | 6 | 62 |
Compd. 1 |
5 | 20 | 9 | 55 | 8 | 60 | 10 | 48 | 7 | 63 |
Compd. 1 |
10 | 25 | 16 | 38 | 11 | 58 | 13 | 48 | 8 | 67 |
Compd. 1 |
25 | 29 | 15 | 48 | 11 | 63 | 16 | 45 | 13 | 56 |
Compd. 1 |
50 | 40 | 21 | 47 | 15 | 62 | 20 | 50 | 12 | 69 |
Compd. 1 |
100 | 42 | 25 | 41 | 18 | 58 | 24 | 43 | 15 | 64 |
Average inhibition (%) (at the range of 5-100 µg/ml) | 45.6 | 60.4 | 46.8 | 63.7 |
BQL = Below Quantitation Limit NA = Not Applicable Rows 1-4 not included in the curve |
Exp. Group | Treatment | In-vitro activation | ||
Article | Mice/group |
Cells/ | Compound | 1 RS |
A1 | Control | |||
12 |
4 | 2.5 × 106 | |
|
5 × 106 | ||||
|
25 5 µg/ |
4 | 2.5 × 106 | |
5 × 106 | ||||
|
50 µg/ |
4 | 2.5 × 106 | |
5 × 106 | ||||
|
100 µg/ |
4 | 2.5 × 106 | |
5 × 106 | ||||
|
200 µg/ |
4 | 2.5 × 106 | |
5 × 106 |
Claims (29)
- A pharmaceutical composition comprising:an aqueous carrier;from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt ofa peptide comprising consecutive amino acids having the sequence(i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11) wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala;(ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;(iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;(iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;(v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;(vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;(viii) FSGYYWS (SEQ ID NO:8);(ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or(x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10), anda substituted β-cyclodextrin as a solubility enhancer selected, and,wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; andwherein the composition has a pH between 4 and 9.
- The pharmaceutical composition of claim 1, wherein at least 0.5 mg/ml of the composition is the pharmaceutically acceptable salt of the peptide.
- The pharmaceutical composition of claim 1 or 2, wherein the peptide has a sequence selected from the group consisting of:NH2- Thr Gly Tyr Tyr Met Gln Trp Val Lys Gln Ser Pro Glu Lys Ser Leu Glu-Trp Ile Gly-COOH (SEQ ID NO:1) ;NH2- Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Ala Lys Ala Thr-COOH (SEQ ID NO:2) ;NH2- Tyr Tyr Cys Ala Arg Phe Leu Tip Glu Pro Tyr Ala Met Asp Tyr Trp Gly Gln Gly Ser-COOH (SEQ ID NO:3) ;NH2- Gly Tyr Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly-COOH (SEQ ID NO:4) ;NH2- Tyr Tyr Cys Ala Arg Ser Gly Arg Tyr Gly Asn Tyr Trp Gly Gln Thr Leu - COOH (SEQ ID NO:5) ;NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:6);NH2- Phe Ser Gly Tyr Tyr Trp Ser-COOH (SEQ I D NO:8) ;NH2- Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Lys Thr Ser Leu Lys Ser-COOH (SEQ ID NO:9); andNH2- Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp Tyr Tyr Tyr Gly Met Asp Val-COOH (SEQ ID NO:10).
- The pharmaceutical composition of claim 1, wherein the peptide comprises consecutive amino acids having the sequenceX33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16)wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser.
- The pharmaceutical composition of any one of claims 1-4, wherein the peptide is SEQ ID NO.6.
- The pharmaceutical composition of any one of claims 1-5, wherein the substituted β-cyclodextrin is a hydroxypropyl, a sulfobutyl ether, or a sulfopropyl ether substituted β-cyclodextrin.
- The pharmaceutical composition of claim 6, wherein the substituted β-cyclodextrin is a substituted sulfobutyl ether β-cyclodextrin.
- The pharmaceutical composition of any one of claims 1-7, wherein the concentration of peptide in solution is at least 1 mg/ml.
- The pharmaceutical composition of any one of claims 1-7, wherein the concentration of peptide in solution is at least 2.5 mg/ml.
- The pharmaceutical composition of any one of claims 1-9, wherein the composition has a pH between 6.5 and 8.5.
- The pharmaceutical composition of claim 10, wherein the composition has a pH between 7.5 and 8.5.
- The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutically acceptable salt is an acetate salt.
- The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt is an acetate salt, and the substituted β-cyclodextrin is hepta-(sulfobutyl ether)-β-cyclodextrin.
- A process for manufacturing the pharmaceutical composition of any one of claims 1-13 comprising the steps of:a) preparing a solution of a substituted β-cyclodextrin in an aqueous carrier at a predetermined concentration;b) adding a predetermined amount of a pharmaceutically acceptable salt ofa peptide comprising amino acids having the sequence(i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO:11) wherein X1 is Met, Ala or Val; X2 is Gln, Asp, Glu or Arg; X3 is Trp or Ala; X4 is Val or Ser; and X5 is Lys, Glu or Ala;(ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO:12) wherein X6 and X7 are each Thr, Val or Ala; X8 is Tyr or Phe; X9 is Asn or Asp; X10 is Gln or Glu; X11 is Lys or Glu, and X12 is Phe or Tyr;(iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO:13) wherein X13 is Phe, Thr or Gly; X14 is Leu, Ala or Ser; X15 is Trp or Ala; X16 is Glu or Lys; X17 is Met or Ala, and X18 is Asp, Lys or Ser;(iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO:14) wherein X19 is Met or Ala; X20 is Asn, Asp or Arg; X21 is Trp or Ala; X22 is Val or Ser; X23 is Lys or Glu; X24 is Gln or Ala; X25 is Lys or Glu, and X26 is Ser or Ala;(v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO:15) wherein X27 is Ser or Phe; X28 is Gly or Ala; X29 is Arg, Ala or Glu; X30 is Asn or Asp; X31 is Tyr or Phe, and X32 is Trp, His or Ala;(vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO:16) wherein X33 is Gly or Thr Gly; X34 is Arg or Lys; X35 is Pro or Ser; X36 is Gly or Glu; X37 is Lys or Asp; and X38 is Glu, Leu or Ser;(viii) FSGYYWS (SEQ ID NO:8);(ix) EINHSGSTNYKTSLKS (SEQ ID NO:9); or(x) GLLRGGWNDVDYYYGMDV (SEQ ID NO:10),c) adjusting the pH of the solution of step b) until the peptide dissolves in the solution; andd) if necessary, adjusting the pH of the solution of step c) to a pH of 4-9, thereby manufacturing the pharmaceutical composition.
- The process of claim 14, wherein the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition of 2.5mg/ml, 2.0mg/ml, 1.0mg/ml, 0.5 mg/ml or 0.1 mg/ml.
- The process of any one of claims 14 or 15, wherein step b) further comprises mixing the solution for 1 hour.
- The process of any one of claims 14-16, wherein in step c) the pH is adjusted using HCl or NaOH 1.0N.
- The process of any one of claims 14-17, further comprising filtering the solution of step d) through a cellulose acetate filter.
- A process of lyophilizing the pharmaceutical composition of any one of claims 1-13, comprising the steps of:a) lowering the temperature of the pharmaceutical composition to -40°C;b) holding the temperature at -40°C for a predetermined time;c) raising the temperature of the solution to 20°C;d) holding the temperature at 20°C for a predetermined time; ande) reducing the pressure and holding the temperature at 20°C for a predetermined time, thereby lyophilizing the pharmaceutical composition.
- The process of claim 19, whereinstep a) is performed within 2 hours;step b) is performed within 3 hours;step c) is performed over 13 hours and at a pressure of 110µbar;step d) is performed over 13 hours and at a pressure of 110µbar; andstep e) is performed over 5 hours and the pressure is reduced to 10µbar.
- A process of lyophilizing the pharmaceutical composition of any one of claims 1-13, comprising the steps of:a) lowering the temperature of the pharmaceutical composition to -45°C;b) holding the temperature at -45°C for a predetermined time;c) raising the temperature of the solution to -20°C;d) raising the temperature of the solution to 25°C; ande) holding the temperature at 25°C for a predetermined time, thereby lyophilizing the pharmaceutical composition.
- The process of claim 21, whereinstep a) is performed within 6 hours;step b) is performed within 3 hours;step c) is performed over 19 hours and at a pressure of 150µbar;step d) is performed over 13 hours and at a pressure of 150µbar; andstep e) is performed over 8 hours and at a pressure of 150µbar.
- A lyophilized pharmaceutical composition prepared by the process of any one of claims 19-22.
- The lyophilized pharmaceutical composition of claim 23, wherein the water content of the composition is less than 5%.
- The lyophilized pharmaceutical composition of claim 24, wherein the water content of the composition is less than 4.0%.
- The lyophilized pharmaceutical composition of claim 25, wherein the water content of the composition is less then 3.5%.
- Use of the pharmaceutical composition of any of claims 1-13 or 23-26 in the manufacture of a medicament for alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject.
- The pharmaceutical composition of any one of claims 1-13 or 23-26 for use in treating SLE in a human subject.
- A packaged pharmaceutical composition comprised of:a packaging material; anda predetermined amount of the lyophilized pharmaceutical composition of claim 23.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43991803P | 2003-01-14 | 2003-01-14 | |
US439918P | 2003-01-14 | ||
PCT/US2004/000948 WO2004064787A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1594434A2 EP1594434A2 (en) | 2005-11-16 |
EP1594434A4 EP1594434A4 (en) | 2008-09-10 |
EP1594434B1 true EP1594434B1 (en) | 2016-09-07 |
Family
ID=32771757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04702215.7A Expired - Lifetime EP1594434B1 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Country Status (21)
Country | Link |
---|---|
US (3) | US20050008634A1 (en) |
EP (1) | EP1594434B1 (en) |
JP (2) | JP4817068B2 (en) |
KR (1) | KR20050100617A (en) |
CN (1) | CN1774259B (en) |
AU (1) | AU2004206842A1 (en) |
BR (1) | BRPI0406745A (en) |
CA (1) | CA2513320C (en) |
CO (1) | CO5640143A2 (en) |
CR (1) | CR7938A (en) |
DK (1) | DK1594434T3 (en) |
EA (1) | EA009123B1 (en) |
EC (1) | ECSP055961A (en) |
ES (1) | ES2606464T3 (en) |
IL (1) | IL169574A (en) |
IS (1) | IS7972A (en) |
MX (1) | MXPA05007549A (en) |
NO (1) | NO20053773L (en) |
NZ (1) | NZ541658A (en) |
WO (1) | WO2004064787A2 (en) |
ZA (1) | ZA200506206B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
EA008438B1 (en) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Parenteral formulations of a peptide for the treatment of systemic lupus erhythematosus |
DK1594434T3 (en) * | 2003-01-14 | 2017-01-02 | Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science | Parenteral formulations of peptide for the treatment of systemic lupus erythematosus |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
PE20120169A1 (en) * | 2008-11-17 | 2012-02-29 | Genentech Inc | METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS |
US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
SG11201500123XA (en) * | 2012-07-12 | 2015-02-27 | Sanofi Sa | Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
KR102112119B1 (en) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | Alkylated Cyclodextrin Compositions and Processes for Preparing and using the same |
WO2014193611A1 (en) * | 2013-05-29 | 2014-12-04 | Oklahoma Medical Research Foundation | Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity |
US10189881B2 (en) | 2013-07-26 | 2019-01-29 | The Regents Of The University Of California | MPS peptides and use thereof |
WO2015095789A2 (en) * | 2013-12-20 | 2015-06-25 | The Regents Of The University Of California | Suppression of allergic lung inflammation and hyperreactivity |
WO2016029179A1 (en) | 2014-08-22 | 2016-02-25 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
AU2016380988B2 (en) | 2015-12-30 | 2022-07-21 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
TWI797073B (en) * | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | Pharmaceutical composition comprising bispecific antibody constructs |
AU2018205885A1 (en) * | 2017-01-05 | 2019-06-27 | Yeda Research And Development Co. Ltd. | Peptides for treating Sjogren's syndrome |
CN110476031A (en) * | 2017-04-04 | 2019-11-19 | 日东电工株式会社 | It is freeze-dried the manufacturing method and its manufacturing device of body |
US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
WO2019108285A1 (en) * | 2017-11-30 | 2019-06-06 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
CN112143707A (en) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | Immune cell for treating autoimmune cell and application thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60184098A (en) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | Novel peptide and diuretic comprising it as active ingredient |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5126249A (en) * | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (en) * | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
US6613536B1 (en) * | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
IL120503A0 (en) * | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
US20020054872A1 (en) * | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
SE9802938D0 (en) * | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
EA008438B1 (en) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Parenteral formulations of a peptide for the treatment of systemic lupus erhythematosus |
DK1594434T3 (en) * | 2003-01-14 | 2017-01-02 | Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science | Parenteral formulations of peptide for the treatment of systemic lupus erythematosus |
US7018891B2 (en) * | 2003-12-16 | 2006-03-28 | International Business Machines Corporation | Ultra-thin Si channel CMOS with improved series resistance |
-
2004
- 2004-01-14 DK DK04702215.7T patent/DK1594434T3/en active
- 2004-01-14 BR BR0406745-2A patent/BRPI0406745A/en not_active IP Right Cessation
- 2004-01-14 CA CA2513320A patent/CA2513320C/en not_active Expired - Lifetime
- 2004-01-14 JP JP2006500956A patent/JP4817068B2/en not_active Expired - Fee Related
- 2004-01-14 EP EP04702215.7A patent/EP1594434B1/en not_active Expired - Lifetime
- 2004-01-14 NZ NZ541658A patent/NZ541658A/en unknown
- 2004-01-14 MX MXPA05007549A patent/MXPA05007549A/en not_active Application Discontinuation
- 2004-01-14 US US10/758,397 patent/US20050008634A1/en not_active Abandoned
- 2004-01-14 WO PCT/US2004/000948 patent/WO2004064787A2/en not_active Application Discontinuation
- 2004-01-14 KR KR1020057013098A patent/KR20050100617A/en not_active Application Discontinuation
- 2004-01-14 ES ES04702215.7T patent/ES2606464T3/en not_active Expired - Lifetime
- 2004-01-14 AU AU2004206842A patent/AU2004206842A1/en not_active Abandoned
- 2004-01-14 EA EA200501131A patent/EA009123B1/en not_active IP Right Cessation
- 2004-01-14 CN CN2004800069872A patent/CN1774259B/en not_active Expired - Lifetime
-
2005
- 2005-07-06 IL IL169574A patent/IL169574A/en active IP Right Grant
- 2005-08-03 ZA ZA200506206A patent/ZA200506206B/en unknown
- 2005-08-05 IS IS7972A patent/IS7972A/en unknown
- 2005-08-08 NO NO20053773A patent/NO20053773L/en not_active Application Discontinuation
- 2005-08-09 CR CR7938A patent/CR7938A/en not_active Application Discontinuation
- 2005-08-10 CO CO05079328A patent/CO5640143A2/en not_active Application Discontinuation
- 2005-08-11 EC EC2005005961A patent/ECSP055961A/en unknown
-
2008
- 2008-11-10 US US12/291,439 patent/US20090169559A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011066343A patent/JP2011173888A/en active Pending
-
2012
- 2012-04-23 US US13/453,979 patent/US20130023485A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130023485A1 (en) | 2013-01-24 |
CN1774259B (en) | 2011-12-28 |
ZA200506206B (en) | 2006-12-27 |
AU2004206842A1 (en) | 2004-08-05 |
NZ541658A (en) | 2008-04-30 |
EA200501131A1 (en) | 2006-04-28 |
JP2006517540A (en) | 2006-07-27 |
MXPA05007549A (en) | 2006-05-19 |
CR7938A (en) | 2006-05-31 |
US20090169559A1 (en) | 2009-07-02 |
WO2004064787A2 (en) | 2004-08-05 |
ECSP055961A (en) | 2006-04-19 |
EP1594434A2 (en) | 2005-11-16 |
CN1774259A (en) | 2006-05-17 |
IL169574A (en) | 2015-08-31 |
CA2513320C (en) | 2018-03-27 |
US20050008634A1 (en) | 2005-01-13 |
IS7972A (en) | 2006-07-15 |
NO20053773D0 (en) | 2005-08-08 |
IL169574A0 (en) | 2007-07-04 |
CA2513320A1 (en) | 2004-08-05 |
ES2606464T3 (en) | 2017-03-24 |
JP4817068B2 (en) | 2011-11-16 |
CO5640143A2 (en) | 2006-05-31 |
KR20050100617A (en) | 2005-10-19 |
EP1594434A4 (en) | 2008-09-10 |
JP2011173888A (en) | 2011-09-08 |
EA009123B1 (en) | 2007-10-26 |
BRPI0406745A (en) | 2005-12-20 |
WO2004064787A3 (en) | 2005-12-15 |
DK1594434T3 (en) | 2017-01-02 |
NO20053773L (en) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130023485A1 (en) | Parenteral formulations of peptides for the treatment of systematic lupus erythematosus | |
US20200283517A1 (en) | Methods for treating chron's disease using an anti-il23 antibody | |
ES2973062T3 (en) | Anti-CD40 antibodies and their uses | |
US20080287366A1 (en) | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus | |
EP2379584A1 (en) | Soluble polypeptides for use in treating autoimmune and inflammatory disorders | |
CN111741763A (en) | Pharmaceutical compositions comprising APL-type peptides | |
EP1370575B1 (en) | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus | |
JP2015501831A (en) | Modified peptides and their use for the treatment of autoimmune diseases | |
US20230338526A1 (en) | Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseases | |
EP3717011B1 (en) | Method of treating or preventing ischemia-reperfusion injury | |
CN113194996A (en) | Clazalizumab for the treatment of chronic antibody-mediated organ transplant rejection | |
WO2023025249A1 (en) | Pharmaceutical composition containing fusion protein | |
CN110612120A (en) | Methods of treating pediatric disorders using antibodies specific for alpha 4 beta 7 integrin (vedolizumab) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050811 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076056 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/00 20060101AFI20051221BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080813 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 51/10 20060101ALI20080807BHEP Ipc: A61K 47/40 20060101ALI20080807BHEP Ipc: A61K 38/00 20060101AFI20051221BHEP |
|
17Q | First examination report despatched |
Effective date: 20090415 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076056 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: YEDA RESEARCH AND DEVELOPMENT CO. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160401 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 826225 Country of ref document: AT Kind code of ref document: T Effective date: 20161015 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004049902 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG INHABER Ref country code: CH Ref legal event code: NV Representative=s name: ROMAN VUILLE, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20161222 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 826225 Country of ref document: AT Kind code of ref document: T Effective date: 20160907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170109 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161207 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004049902 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170608 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170114 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20040114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160907 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602004049902 Country of ref document: DE Representative=s name: 2K PATENT- UND RECHTSANWAELTE PARTNERSCHAFT MB, DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160907 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20221212 Year of fee payment: 20 Ref country code: NL Payment date: 20221220 Year of fee payment: 20 Ref country code: IE Payment date: 20221209 Year of fee payment: 20 Ref country code: GB Payment date: 20221208 Year of fee payment: 20 Ref country code: FR Payment date: 20221208 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20230109 Year of fee payment: 20 Ref country code: ES Payment date: 20230213 Year of fee payment: 20 Ref country code: DK Payment date: 20230111 Year of fee payment: 20 Ref country code: CH Payment date: 20230106 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20221213 Year of fee payment: 20 Ref country code: DE Payment date: 20221213 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 602004049902 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL Ref country code: DK Ref legal event code: EUP Expiry date: 20240114 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20240113 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20240126 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20240113 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240115 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240114 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240115 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20240113 |